Veterinary Pharmaceuticals Market by Product (Drugs, mAbs, Immunomodulators, Medicated Feed Additives), Route of Administration, Formulation Type, Indication, Animal Type (Companion, Livestock), Distribution Channel, End User-Global Forecast to 2031
The global veterinary pharmaceuticals market is projected to grow at a CAGR of 6.3% from 2026 to 2031, reflecting steady expansion across both companion and livestock segments. Growth is supported by rising pet humanization, increasing prevalence of chronic and infectious diseases, and higher spending on advanced therapeutics. In livestock, productivity pressures and stricter food safety standards continue to drive pharmaceutical demand, sustaining consistent mid-single-digit market growth.
“By product type, the monoclonal antibodies segment is expected to witness the fastest growth rate during the forecast period.”
The monoclonal antibodies segment is expected to grow fastest in the global veterinary pharmaceuticals market, supported by a growing preference for targeted and durable treatment options, especially in companion animals. The rising burden of chronic disorders, including atopic dermatitis, osteoarthritis, and immune-mediated conditions, is boosting demand. These therapies offer precise action, fewer adverse effects, and longer dosing intervals, improving compliance. Continued investment in biologics development and the expanding premium pet care market are further driving segment expansion.
“By indication, the dermatological diseases segment has accounted for the largest share in the Veterinary pharmaceuticals market in 2025.”
The dermatological conditions segment is projected to hold the largest share of the global veterinary pharmaceuticals market in 2025, primarily due to the widespread occurrence of skin-related disorders in both companion and livestock animals. Common conditions such as atopic dermatitis, parasitic infections, fungal diseases, and bacterial skin infections require ongoing management and medication. Growing pet adoption, heightened focus on animal hygiene, and strong demand for anti-parasitic, antifungal, and anti-inflammatory treatments continue to reinforce the segment’s dominant position.
“North America dominated the global veterinary pharmaceuticals market in 2025.”
North America leads the veterinary pharmaceuticals market in 2025, supported by a mature animal healthcare ecosystem and strong purchasing power. The region records high spending on companion animal treatments and maintains a large commercial livestock base. Robust R&D investments, rapid approval pathways for innovative drugs, and the strong presence of established manufacturers further strengthen its position. Well-developed distribution networks and growing awareness of preventive animal care also contribute to its leading market position.
Breakdown of supply-side primary interviews:
This report examines the veterinary pharmaceuticals market by product type, route of administration, formulation type, indications, animal type, distribution channel, end user, and region. It also examines factors (such as drivers, restraints, opportunities, and challenges) that affect market growth. It analyzes market opportunities and challenges and provides details on the competitive landscape for market leaders. Furthermore, the report analyzes micro-markets by their individual growth trends and forecasts market segment revenue across five main regions and their respective countries.
Reasons to Buy the Report
The report can help established firms as well as new entrants/smaller firms gauge the market pulse, which, in turn, would help them gain a greater share. Firms purchasing the report could use one or a combination of the following five strategies.
This report provides insights into the following pointers:
“By product type, the monoclonal antibodies segment is expected to witness the fastest growth rate during the forecast period.”
The monoclonal antibodies segment is expected to grow fastest in the global veterinary pharmaceuticals market, supported by a growing preference for targeted and durable treatment options, especially in companion animals. The rising burden of chronic disorders, including atopic dermatitis, osteoarthritis, and immune-mediated conditions, is boosting demand. These therapies offer precise action, fewer adverse effects, and longer dosing intervals, improving compliance. Continued investment in biologics development and the expanding premium pet care market are further driving segment expansion.
“By indication, the dermatological diseases segment has accounted for the largest share in the Veterinary pharmaceuticals market in 2025.”
The dermatological conditions segment is projected to hold the largest share of the global veterinary pharmaceuticals market in 2025, primarily due to the widespread occurrence of skin-related disorders in both companion and livestock animals. Common conditions such as atopic dermatitis, parasitic infections, fungal diseases, and bacterial skin infections require ongoing management and medication. Growing pet adoption, heightened focus on animal hygiene, and strong demand for anti-parasitic, antifungal, and anti-inflammatory treatments continue to reinforce the segment’s dominant position.
“North America dominated the global veterinary pharmaceuticals market in 2025.”
North America leads the veterinary pharmaceuticals market in 2025, supported by a mature animal healthcare ecosystem and strong purchasing power. The region records high spending on companion animal treatments and maintains a large commercial livestock base. Robust R&D investments, rapid approval pathways for innovative drugs, and the strong presence of established manufacturers further strengthen its position. Well-developed distribution networks and growing awareness of preventive animal care also contribute to its leading market position.
Breakdown of supply-side primary interviews:
- By Company Type: Tier 1 – 45%, Tier 2 – 20%, and Tier 3 – 35%
- By Designation: C-level – 35%, Director-level – 25%, and Others – 40%
- By Region: North America - 40%, Europe – 25%, APAC – 20%, Latin America – 10%, Middle East & Africa – 5%
This report examines the veterinary pharmaceuticals market by product type, route of administration, formulation type, indications, animal type, distribution channel, end user, and region. It also examines factors (such as drivers, restraints, opportunities, and challenges) that affect market growth. It analyzes market opportunities and challenges and provides details on the competitive landscape for market leaders. Furthermore, the report analyzes micro-markets by their individual growth trends and forecasts market segment revenue across five main regions and their respective countries.
Reasons to Buy the Report
The report can help established firms as well as new entrants/smaller firms gauge the market pulse, which, in turn, would help them gain a greater share. Firms purchasing the report could use one or a combination of the following five strategies.
This report provides insights into the following pointers:
- Analysis of key drivers, restraints, opportunities, and challenges influencing the growth of the veterinary pharmaceuticals market.
- Product Development/Innovation: Detailed insights on upcoming technologies, research and development activities, and product launches in the veterinary pharmaceuticals market.
- Market Development: Comprehensive information about lucrative emerging markets. The report analyzes the markets for various types of catheterization procedures across regions.
- Market Diversification: Exhaustive information about products, untapped regions, recent developments, and investments in the veterinary pharmaceuticals market.
- Competitive Assessment: In-depth assessment of market shares, strategies, products, distribution networks, and manufacturing capabilities of the leading players in the veterinary pharmaceuticals market.
1 INTRODUCTION
1.1 STUDY OBJECTIVES
1.2 MARKET DEFINITION
1.2.1 INCLUSIONS AND EXCLUSIONS
1.3 MARKET SCOPE
1.3.1 MARKETS COVERED
1.3.2 YEARS CONSIDERED
1.4 CURRENCY CONSIDERED
1.5 STAKEHOLDERS
2 EXECUTIVE SUMMARY
2.1 MARKET HIGHLIGHTS AND KEY INSIGHTS
2.2 KEY MARKET PARTICIPANTS: MAPPING OF STRATEGIC DEVELOPMENTS
2.3 DISRUPTIVE TRENDS IN VETERINARY PHARMACEUTICALS MARKET
2.4 HIGH-GROWTH SEGMENTS
2.5 REGIONAL SNAPSHOT: MARKET SIZE, GROWTH RATE, AND FORECAST
3 PREMIUM INSIGHTS
3.1 ATTRACTIVE OPPORTUNITIES FOR PLAYERS IN VETERINARY PHARMACEUTICALS MARKET
3.2 ASIA PACIFIC: VETERINARY PHARMACEUTICALS MARKET, BY PRODUCT TYPE AND COUNTRY
3.3 VETERINARY PHARMACEUTICALS MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES
3.4 VETERINARY PHARMACEUTICALS MARKET: DEVELOPING VS. DEVELOPED ECONOMIES, 2026?2031
4 MARKET OVERVIEW
4.1 INTRODUCTION
4.2 MARKET DYNAMICS
4.2.1 DRIVERS
4.2.1.1 Rising companion animal ownership and pet humanization
4.2.1.2 Growing prevalence of infectious and dermatological diseases in animals
4.2.1.3 Increasing demand for animal-derived food products
4.2.2 RESTRAINTS
4.2.2.1 Growing concerns over antimicrobial resistance (AMR)
4.2.2.2 Stringent regulatory approval processes for veterinary drugs
4.2.3 OPPORTUNITIES
4.2.3.1 Rising demand for parasiticides and dermatology products
4.2.3.2 Growth potential in rural and low-income regions
4.2.4 CHALLENGES
4.2.4.1 Monitoring drug residues in food-producing animals
4.2.4.2 Balancing animal welfare, productivity, and compliance requirements
4.3 UNMET NEEDS AND WHITE SPACES
4.4 INTERCONNECTED MARKET AND CROSS-SECTOR OPPORTUNITIES
4.4.1 INTERCONNECTED MARKETS
4.4.2 CROSS-SECTOR OPPORTUNITIES
4.5 STRATEGIC MOVES BY TIER-1/2/3 PLAYERS
5 INDUSTRY TRENDS
5.1 PORTER’S FIVE FORCES ANALYSIS
5.1.1 THREAT OF NEW ENTRANTS
5.1.2 THREAT OF SUBSTITUTES
5.1.3 BARGAINING POWER OF SUPPLIERS
5.1.4 BARGAINING POWER OF BUYERS
5.1.5 INTENSITY OF COMPETITIVE RIVALRY
5.2 MACROECONOMICS INDICATORS
5.2.1 INTRODUCTION
5.2.2 GDP TRENDS AND FORECAST
5.2.3 TRENDS IN GLOBAL ANIMAL HEALTHCARE INDUSTRY
5.2.4 TRENDS IN GLOBAL VETERINARY PHARMACEUTICALS INDUSTRY
5.3 VALUE CHAIN ANALYSIS
5.4 SUPPLY CHAIN ANALYSIS
5.5 ECOSYSTEM ANALYSIS
5.6 PRICING ANALYSIS
5.6.1 AVERAGE SELLING PRICE TREND OF PRODUCTS, BY KEY PLAYERS, 2023–2025
5.6.2 AVERAGE SELLING PRICE TREND OF FORMULATION TYPES, BY KEY PLAYERS, 2023–2025
5.6.3 AVERAGE SELLING PRICE TREND OF PRODUCTS, BY REGION, 2023–2025
5.7 TRADE ANALYSIS
5.7.1 IMPORT DATA FOR HS CODE 30, 2021–2024
5.7.1.1 Import scenario (HS code 30)
5.7.2 EXPORT DATA FOR HS CODE 30, 2021–2024
5.7.3 EXPORT SCENARIO (HS CODE 30)
5.8 KEY CONFERENCES AND EVENTS IN 2026–2027
5.9 TRENDS/DISRUPTIONS IMPACTING CUSTOMER BUSINESS
5.10 INVESTMENT AND FUNDING SCENARIO
5.11 CASE STUDY ANALYSIS
5.11.1 ZOETIS INC.
5.11.2 BOEHRINGER INGELHEIM ANIMAL HEALTH
5.11.3 MERCK ANIMAL HEALTH
5.11.4 ELANCO ANIMAL HEALTH
5.11.5 CEVA SANTE ANIMALE
5.12 IMPACT OF 2025 US TARIFF - VETERINARY PHARMACEUTICALS MARKET
5.12.1 INTRODUCTION
5.12.2 KEY TARIFF RATES
5.12.3 PRICE IMPACT ANALYSIS
5.12.4 IMPACT ON REGIONS
5.12.4.1 North America
5.12.4.2 Europe
5.12.4.3 Asia Pacific
5.12.5 IMPACT ON END-USE INDUSTRIES
5.12.5.1 Veterinary hospitals & clinics
5.12.5.2 Home care settings
5.12.5.3 Livestock farms
5.12.5.4 Rescue centers & NGOs
5.12.5.5 Other end users
6 TECHNOLOGICAL ADVANCEMENTS, AI-DRIVEN IMPACT, PATENTS, INNOVATIONS, AND FUTURE APPLICATIONS
6.1 TECHNOLOGY ANALYSIS
6.1.1 KEY EMERGING TECHNOLOGIES
6.1.1.1 Controlled release formulation
6.1.1.2 Biologics and monoclonal antibodies
6.1.2 COMPLEMENTARY TECHNOLOGIES
6.1.2.1 Digital health and telemedicine platforms
6.1.2.2 Veterinary biomarker analysis
6.1.3 ADJACENT TECHNOLOGIES
6.1.3.1 Wearable animal health monitoring devices
6.1.3.2 Stem cell therapy and regenerative medicine
6.2 TECHNOLOGY/PRODUCT ROADMAP
6.3 PATENT ANALYSIS
6.3.1 PUBLICATION TRENDS FOR VETERINARY PHARMACEUTICALS
6.3.2 INSIGHTS ON PATENT PUBLICATION TRENDS, TOP APPLICANTS AND JURISDICTION FOR VETERINARY PHARMACEUTICALS MARKET, JANUARY 2015–DECEMBER 2025
6.3.3 LIST OF MAJOR PATENTS, 2023–2025
6.4 FUTURE APPLICATIONS
6.4.1 PRECISION LIVESTOCK HEALTH MANAGEMENT
6.4.2 ONCOLOGY AND CHRONIC DISEASE MANAGEMENT
6.4.3 REPRODUCTIVE AND FERTILITY ENHANCEMENT IN LIVESTOCK
6.4.4 INTEGRATED DISEASE SURVEILLANCE AND OUTBREAK CONTROL
6.5 IMPACT OF GEN AI ON VETERINARY PHARMACEUTICALS MARKET
7 REGULATORY LANDSCAPE AND SUSTAINABILITY INITIATIVES
7.1 REGIONAL REGULATIONS AND COMPLIANCE
7.1.1 REGULATORY FRAMEWORK
7.1.1.1 North America
7.1.1.2 Europe
7.1.2 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
7.1.3 INDUSTRY STANDARDS
7.1.3.1 VICH Guidelines (International Co-operation on Harmonisation of Technical Requirements for Registration of Veterinary Medicinal Products)
7.1.3.2 Good Manufacturing Practice (GMP) Standards – PIC/S Guide (PE 009 series)
7.1.3.3 Codex Alimentarius Standards for Veterinary Drug Residues (CXM 2 – Maximum Residue Limits)
7.2 SUSTAINABILITY INITIATIVES
7.2.1 ECO-FRIENDLY AND RECYCLABLE MATERIALS IN VETERINARY PHARMACEUTICALS MARKET
7.2.1.1 Virbac – Eco-pack to reduce single-use plastic in veterinary products
7.2.1.2 Boehringer Ingelheim Animal Health – Renewable energy-powered manufacturing
7.2.1.3 Boehringer Ingelheim – Recyclable veterinary delivery device (Aservo, EquiHaler)
7.3 CERTIFICATIONS, LABELING, ECO-STANDARDS
8 CUSTOMER LANDSCAPE AND BUYER BEHAVIOR
8.1 DECISION-MAKING PROCESS
8.2 KEY STAKEHOLDERS INVOLVED IN BUYING PROCESS AND THEIR EVALUATION CRITERIA
8.2.1 KEY STAKEHOLDERS IN BUYING PROCESS
8.2.2 BUYING CRITERIA
8.3 ADOPTION BARRIERS AND INTERNAL CHALLENGES
8.4 UNMET NEEDS IN VARIOUS END-USE SETTINGS
8.5 MARKET PROFITABILITY
8.5.1 PRODUCT INNOVATION AND DIFFERENTIATION
8.5.2 EXPANSION OF COMPANION ANIMAL HEALTHCARE SPENDING
8.5.3 OPERATIONAL SCALE AND DISTRIBUTION EFFICIENCY
9 VETERINARY PHARMACEUTICALS MARKET, BY PRODUCT TYPE
9.1 INTRODUCTION
9.1.1 VETERINARY PHARMACEUTICALS MARKET VOLUME ANALYSIS BY PRODUCT TYPE, 2024–2031 (THOUSAND UNITS)
9.2 DRUGS
9.2.1 ANTI-BACTERIAL DRUGS
9.2.1.1 Routine use in livestock and companion animals underpins strong market share and steady growth
9.2.2 ANTI-FUNGAL DRUGS
9.2.2.1 Limited approvals and off-label systemic use result in smaller but clinically essential segment
9.2.3 ANTI-VIRAL DRUGS
9.2.3.1 Low current penetration but rising research interest driven by outbreak response and targeted therapies
9.2.4 ANTI-INFLAMMATORY DRUGS
9.2.4.1 Rising surgical volumes and chronic pain management drive stable double-digit market share
9.2.5 ANTI-PARASITIC DRUGS
9.2.5.1 High parasitic burden and preventive care practices sustain market share and strong growth trajectory
9.2.6 ANTI-CANCER DRUGS
9.2.6.1 Increasing pet oncology awareness and advanced therapeutics to fuel growth from small base
9.2.7 CARDIOVASCULAR AND RENAL DRUGS
9.2.7.1 Rising diagnosis of chronic heart and kidney disorders supports steady mid-single-digit market share
9.2.8 GASTROINTESTINAL DRUGS
9.2.8.1 High incidence of digestive disorders and dietary transitions drive sustained demand
9.2.9 OTHER DRUGS
9.3 MONOCLONAL ANTIBODIES
9.3.1 TARGETED BIOLOGICS AND RISING COMPANION ANIMAL THERAPEUTICS TO DRIVE DEMAND
9.4 IMMUNOMODULATORS
9.4.1 INCREASING FOCUS ON IMMUNE-MEDIATED DISEASES AND PREVENTIVE HEALTH TO SUPPORT GRADUAL EXPANSION FROM SMALLER BASE
9.5 MEDICATED FEED ADDITIVES
9.5.1 AMINO ACIDS
9.5.1.1 Protein optimization and feed cost efficiency to drive demand
9.5.2 ENZYMES
9.5.2.1 Improved nutrient digestibility and cost optimization to support steady adoption
9.5.3 VITAMINS AND MINERALS
9.5.3.1 Essential micronutrient supplementation ensures largest market share
9.5.4 OTHER MEDICATED FEED ADDITIVES
10 VETERINARY PHARMACEUTICALS MARKET, BY ROUTE OF ADMINISTRATION
10.1 INTRODUCTION
10.2 ORAL
10.2.1 EASE OF DOSING AND HIGH COMPLIANCE IN COMPANION AND LIVESTOCK ANIMALS
10.3 PARENTERAL
10.3.1 RAPID THERAPEUTIC ACTION AND HIGHER BIOAVAILABILITY IN CRITICAL CARE AND PRODUCTION SETTINGS
10.4 TOPICAL
10.4.1 RISING DERMATOLOGY CASES AND DEMAND FOR LOCALIZED, NON-INVASIVE TREATMENTS
10.5 OTHER ROUTES OF ADMINISTRATION
11 VETERINARY PHARMACEUTICALS MARKET, BY FORMULATION TYPE
11.1 INTRODUCTION
11.2 SOLID
11.2.1 DOSING STABILITY, COST EFFICIENCY, AND EASE OF LARGE-SCALE ADMINISTRATION IN LIVESTOCK AND COMPANION ANIMALS
11.3 LIQUID
11.3.1 RAPID ABSORPTION, FLEXIBLE DOSING, AND SUITABILITY FOR INJECTABLES AND ORAL SUSPENSIONS
11.4 SEMI-SOLID
11.4.1 RISING DERMATOLOGY CASES AND INCREASING COMPANION ANIMAL CARE EXPENDITURE
11.5 AEROSOL/SPRAY
11.5.1 CONVENIENCE, TARGETED DELIVERY, AND REDUCED CROSS-CONTAMINATION RISK
11.6 PREMIX FORMULATIONS
11.6.1 DEMAND FOR MEDICATED FEED AND PREVENTIVE HERD-LEVEL DISEASE MANAGEMENT TO DRIVE MARKET
12 VETERINARY PHARMACEUTICALS MARKET, BY INDICATION
12.1 INTRODUCTION
12.2 INFECTIOUS DISEASES
12.2.1 ZOONOTIC RISK AND LIVESTOCK DISEASE CONTROL PROGRAMS TO DRIVE MARKET
12.3 DERMATOLOGICAL DISEASES
12.3.1 RISING CHRONIC SKIN CONDITIONS AND PREMIUM COMPANION ANIMAL SPENDING TO DRIVE MARKET
12.4 PAIN MANAGEMENT
12.4.1 RISING SURGICAL PROCEDURES AND AGING PET POPULATION TO DRIVE MARKET
12.5 CARDIOVASCULAR AND RENAL DISEASES
12.5.1 INCREASED DIAGNOSIS IN AGING COMPANION ANIMALS TO DRIVE MARKET
12.6 GASTROINTESTINAL DISEASES
12.6.1 HIGH PREVALENCE OF ENTERIC INFECTIONS AND DIETARY DISORDERS TO DRIVE MARKET
12.7 OTHER INDICATIONS
13 VETERINARY PHARMACEUTICALS MARKET, BY ANIMAL TYPE
13.1 INTRODUCTION
13.2 COMPANION ANIMALS
13.2.1 DOGS
13.2.1.1 Increasing population and adoption of dogs to drive market
13.2.2 CATS
13.2.2.1 Emerging trends in feline pharmaceuticals to boost market
13.2.3 HORSES
13.2.3.1 Higher risk of traumatic injuries in horses to drive demand for veterinary pharmaceutical products
13.2.4 OTHER COMPANION ANIMALS
13.3 LIVESTOCK ANIMALS
13.3.1 CATTLE
13.3.1.1 Economic importance of dairy and beef cattle to drive growth
13.3.2 SWINE
13.3.2.1 Growing surgical volume for acute conditions in swine to drive market
13.3.3 POULTRY
13.3.3.1 Growing focus on infection prevention and flock health management to drive market
13.3.4 OTHER LIVESTOCK ANIMALS
14 VETERINARY PHARMACEUTICALS MARKET, BY DISTRIBUTION CHANNEL
14.1 INTRODUCTION
14.2 VETERINARY HOSPITAL PHARMACIES
14.2.1 HIGH IMPORTANCE AND BETTER OPPORTUNITIES IN ON-FARM VETERINARY PHARMACEUTICALS TO DRIVE MARKET
14.3 RETAIL PHARMACIES
14.3.1 RETAIL PHARMACIES TO AID ACCESSIBILITY AND MARKET REACH IN VETERINARY PHARMACEUTICALS
14.4 ONLINE PHARMACIES
14.4.1 CONVENIENCE AND ACCESSIBILITY TO AUGMENT MARKET GROWTH
14.5 DIRECT SALES
14.5.1 DIRECT SALES TO STRENGTHEN MANUFACTURER-TO-CUSTOMER CONNECTIONS
15 VETERINARY PHARMACEUTICALS MARKET, BY END USER
15.1 INTRODUCTION
15.2 VETERINARY HOSPITALS & CLINICS
15.2.1 FIRST POINT OF CONTACT FOR ANIMAL OWNERS AND LIVESTOCK CAREGIVERS
15.3 LIVESTOCK FARMS
15.3.1 GROWING IMPORTANCE AND OPPORTUNITIES IN ON-FARM ANIMAL CARE
15.4 HOME CARE SETTINGS
15.4.1 RISING PET EXPENDITURE TO PROPEL SEGMENT GROWTH
15.5 OTHER END USERS
16 VETERINARY PHARMACEUTICALS MARKET, BY REGION
16.1 INTRODUCTION
16.2 NORTH AMERICA
16.2.1 MACROECONOMIC OUTLOOK FOR NORTH AMERICA
16.2.2 NORTH AMERICA: VETERINARY PHARMACEUTICALS MARKET VOLUME ANALYSIS BY PRODUCT TYPE, 2024–2031 (THOUSAND UNITS)
16.2.3 US
16.2.3.1 Surge in animal healthcare expenditure to boost market
16.2.4 CANADA
16.2.4.1 Growing pet population and advanced veterinary services to drive market
16.3 EUROPE
16.3.1 MACROECONOMIC OUTLOOK FOR EUROPE
16.3.2 EUROPE: VETERINARY PHARMACEUTICALS MARKET VOLUME ANALYSIS BY PRODUCT TYPE, 2024–2031 (THOUSAND UNITS)
16.3.3 GERMANY
16.3.3.1 Increased focus on animal welfare to drive demand for veterinary pharmaceutical products
16.3.4 UK
16.3.4.1 Increasing pet ownership to propel market
16.3.5 FRANCE
16.3.5.1 High standards of veterinary care to provide attractive growth opportunities for market players
16.3.6 ITALY
16.3.6.1 Growing pet owner awareness and increasing livestock population to drive market
16.3.7 SPAIN
16.3.7.1 Increasing awareness of animal health to drive market
16.3.8 REST OF EUROPE
16.4 ASIA PACIFIC
16.4.1 MACROECONOMIC OUTLOOK FOR ASIA PACIFIC
16.4.2 ASIA PACIFIC: VETERINARY PHARMACEUTICALS MARKET VOLUME ANALYSIS BY PRODUCT TYPE, 2024–2031 (THOUSAND UNITS)
16.4.3 JAPAN
16.4.3.1 Surge in pet care expenditure and growing adoption of companion animals to drive market
16.4.4 CHINA
16.4.4.1 Increasing animal healthcare expenditure and advancements in veterinary medicines to drive market
16.4.5 INDIA
16.4.5.1 Increasing livestock population to propel market growth
16.4.6 AUSTRALIA
16.4.6.1 Growing companion animal ownership and rise in animal health awareness to support market growth
16.4.7 SOUTH KOREA
16.4.7.1 Growing pet ownership and advancements in veterinary medicine to favor market growth
16.4.8 PHILIPPINES
16.4.8.1 Tourism-linked pet culture and veterinary advancements to fuel market
16.4.9 REST OF ASIA PACIFIC
16.5 LATIN AMERICA
16.5.1 MACROECONOMIC OUTLOOK FOR LATIN AMERICA
16.5.2 LATIN AMERICA: VETERINARY PHARMACEUTICALS MARKET VOLUME ANALYSIS BY PRODUCT TYPE, 2024–2031 (THOUSAND UNITS)
16.5.3 BRAZIL
16.5.3.1 Growing pet population and rising disposable incomes to drive market
16.5.4 MEXICO
16.5.4.1 Robust livestock base and growing companion animal care to drive market
16.5.5 REST OF LATIN AMERICA
16.6 MIDDLE EAST & AFRICA
16.6.1 MACROECONOMIC OUTLOOK FOR MIDDLE EAST & AFRICA
16.6.2 MIDDLE EAST & AFRICA: VETERINARY PHARMACEUTICALS MARKET VOLUME ANALYSIS BY PRODUCT TYPE, 2024–2031 (THOUSAND UNITS)
16.7 GCC COUNTRIES
16.7.1 KINGDOM OF SAUDI ARABIA (KSA)
16.7.1.1 Vision 2030 investments to drive market
16.7.2 UNITED ARAB EMIRATES (UAE)
16.7.2.1 Increasing adoption of advanced diagnostic technologies to contribute to market growth
16.7.3 REST OF GCC COUNTRIES
16.7.4 REST OF MIDDLE EAST & AFRICA
17 COMPETITIVE LANDSCAPE
17.1 INTRODUCTION
17.1.1 KEY PLAYER COMPETITIVE STRATEGIES/RIGHT TO WIN, 2023–2026
17.2 REVENUE ANALYSIS, 2023–2025
17.3 MARKET SHARE ANALYSIS, 2025
17.3.1 US: VETERINARY PHARMACEUTICALS MARKET SHARE ANALYSIS, 2025
17.3.2 EUROPE: VETERINARY PHARMACEUTICALS MARKET SHARE ANALYSIS, 2025
17.4 PRODUCT/BRAND COMPARISON
17.5 COMPANY EVALUATION MATRIX: KEY PLAYERS, 2025
17.5.1 STARS
17.5.2 EMERGING LEADERS
17.5.3 PERVASIVE PLAYERS
17.5.4 PARTICIPANTS
17.5.5 COMPANY FOOTPRINT: KEY PLAYERS, 2025
17.5.5.1 Company footprint
17.5.5.2 Region footprint
17.5.5.3 Product type footprint
17.5.5.4 Route of administration footprint
17.5.5.5 Indication footprint
17.5.5.6 End user footprint
17.6 COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2025
17.6.1 PROGRESSIVE COMPANIES
17.6.2 RESPONSIVE COMPANIES
17.6.3 DYNAMIC COMPANIES
17.6.4 STARTING BLOCKS
17.6.5 COMPETITIVE BENCHMARKING: STARTUPS/SMES, 2025
17.6.5.1 Detailed list of key startups/SMEs
17.6.5.2 Competitive benchmarking of key startups/SMEs
17.7 COMPANY VALUATION AND FINANCIAL METRICS
17.8 COMPETITIVE SCENARIO
17.8.1 PRODUCT LAUNCHES & APPROVALS
17.8.2 DEALS
17.8.3 EXPANSIONS
17.8.4 OTHER DEVELOPMENTS
18 COMPANY PROFILES
18.1 KEY PLAYERS
18.1.1 ZOETIS INC.
18.1.1.1 Business overview
18.1.1.2 Products offered
18.1.1.3 Recent developments
18.1.1.3.1 Product launches & approvals
18.1.1.3.2 Expansions
18.1.1.3.3 Other developments
18.1.1.4 MnM view
18.1.1.4.1 Right to win
18.1.1.4.2 Strategic choices
18.1.1.4.3 Weaknesses and competitive threats
18.1.2 MERCK & CO., INC
18.1.2.1 Business overview
18.1.2.2 Products offered
18.1.2.3 Recent developments
18.1.2.3.1 Product launches & approvals
18.1.2.3.2 Deals
18.1.2.3.3 Expansions
18.1.2.4 MnM view
18.1.2.4.1 Right to win
18.1.2.4.2 Strategic choices
18.1.2.4.3 Weaknesses and competitive threats
18.1.3 BOEHRINGER INGELHEIM INTERNATIONAL GMBH
18.1.3.1 Business overview
18.1.3.2 Products offered
18.1.3.3 Recent developments
18.1.3.3.1 Product launches & approvals
18.1.3.3.2 Deals
18.1.3.3.3 Expansions
18.1.3.4 MnM view
18.1.3.4.1 Right to win
18.1.3.4.2 Strategic choices
18.1.3.4.3 Weaknesses and competitive threats
18.1.4 ELANCO ANIMAL HEALTH INCORPORATED
18.1.4.1 Business overview
18.1.4.2 Products offered
18.1.4.3 Recent developments
18.1.4.3.1 Product launches & approvals
18.1.4.3.2 Expansions
18.1.4.3.3 Other developments
18.1.4.4 MnM view
18.1.4.4.1 Right to win
18.1.4.4.2 Strategic choices
18.1.4.4.3 Weaknesses and competitive threats
18.1.5 VIRBAC
18.1.5.1 Business overview
18.1.5.2 Products offered
18.1.5.3 Recent developments
18.1.5.3.1 Product launches & approvals
18.1.5.3.2 Deal
18.1.5.3.3 Expansions
18.1.5.4 MnM view
18.1.5.4.1 Right to win
18.1.5.4.2 Strategic choices
18.1.5.4.3 Weaknesses and competitive threats
18.1.6 CEVA
18.1.6.1 Business overview
18.1.6.2 Products offered
18.1.6.3 Recent developments
18.1.6.3.1 Deals
18.1.6.3.2 Expansions
18.1.7 VETOQUINOL
18.1.7.1 Business overview
18.1.7.2 Products offered
18.1.7.3 Recent developments
18.1.7.3.1 Product launches & approvals
18.1.7.3.2 Deals
18.1.8 DECHRA PHARMACEUTICALS PLC
18.1.8.1 Business overview
18.1.8.2 Products offered
18.1.8.3 Recent developments
18.1.8.3.1 Product launches & approvals
18.1.8.3.2 Deals
18.1.8.3.3 Other developments
18.1.9 NORBROOK
18.1.9.1 Business overview
18.1.9.2 Products offered
18.1.9.3 Recent developments
18.1.9.3.1 Product launches & approvals
18.1.9.3.2 Deals
18.1.9.3.3 Expansions
18.1.9.3.4 Other developments
18.1.10 BIMEDA CORPORATE
18.1.10.1 Business overview
18.1.10.2 Products offered
18.1.10.3 Recent developments
18.1.10.3.1 Product launches & approvals
18.1.10.3.2 Deals
18.1.10.3.3 Expansions
18.1.11 HESTER BIOSCIENCES LIMITED
18.1.11.1 Business overview
18.1.11.2 Products offered
18.1.12 INDIAN IMMUNOLOGICALS LTD.
18.1.12.1 Business overview
18.1.12.2 Products offered
18.1.13 ANIMALCARE GROUP PLC
18.1.13.1 Business overview
18.1.13.2 Products offered
18.1.13.3 Recent developments
18.1.13.3.1 Deals
18.1.13.3.2 Product launches & approvals
18.1.14 KYORITSU SEIYAKU CORPORATION
18.1.14.1 Business overview
18.1.14.2 Products offered
18.1.14.3 Recent developments
18.1.14.3.1 Product launches & approvals
18.1.14.3.2 Deals
18.1.15 CALIER
18.1.15.1 Business overview
18.1.15.2 Products offered
18.1.15.3 Recent developments
18.1.15.3.1 Product launches & approvals
18.2 OTHER PLAYERS
18.2.1 DOPHARMA
18.2.2 PHARMGATE ANIMAL HEALTH
18.2.3 BIOVETA, A.S.
18.2.4 NEXTMUNE
18.2.5 TRIVIUMVET
18.2.6 DOMES PHARMA
18.2.7 UNIVET LIMITED
18.2.8 CENAVISA, S.L.
18.2.9 FATRO S.P.A.
18.2.10 CHANELLE PHARMA
19 RESEARCH METHODOLOGY
19.1 RESEARCH DATA
19.1.1 SECONDARY DATA
19.1.1.1 Key data from secondary sources
19.1.2 PRIMARY DATA
19.1.2.1 Key data from primary sources
19.1.2.2 Key industry insights
19.1.2.3 Key industry insights
19.2 MARKET SIZE ESTIMATION
19.3 GROWTH FORECAST
19.3.1 KEY INDUSTRY INSIGHTS
19.4 MARKET BREAKDOWN AND DATA TRIANGULATION
19.5 RESEARCH ASSUMPTIONS
19.6 RESEARCH LIMITATIONS
19.7 RISK ASSESSMENT
20 APPENDIX
20.1 DISCUSSION GUIDE
20.2 KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL
20.3 CUSTOMIZATION OPTIONS
20.3.1 PRODUCT ANALYSIS
20.3.2 US END USER ANALYSIS
20.3.3 GEOGRAPHIC ANALYSIS
20.3.4 COMPANY INFORMATION
20.3.5 REGIONAL/COUNTRY LEVEL MARKET SHARE ANALYSIS
20.3.6 COUNTRY LEVEL VOLUME ANALYSIS BY PRODUCT TYPE
20.3.7 BY PRODUCT TYPE MARKET SHARE ANALYSIS (TOP 5 PLAYERS)
20.3.8 ANY CONSULTS/CUSTOM REQUIREMENTS AS PER CLIENT REQUEST
20.4 RELATED REPORTS
20.5 AUTHOR DETAILS
1.1 STUDY OBJECTIVES
1.2 MARKET DEFINITION
1.2.1 INCLUSIONS AND EXCLUSIONS
1.3 MARKET SCOPE
1.3.1 MARKETS COVERED
1.3.2 YEARS CONSIDERED
1.4 CURRENCY CONSIDERED
1.5 STAKEHOLDERS
2 EXECUTIVE SUMMARY
2.1 MARKET HIGHLIGHTS AND KEY INSIGHTS
2.2 KEY MARKET PARTICIPANTS: MAPPING OF STRATEGIC DEVELOPMENTS
2.3 DISRUPTIVE TRENDS IN VETERINARY PHARMACEUTICALS MARKET
2.4 HIGH-GROWTH SEGMENTS
2.5 REGIONAL SNAPSHOT: MARKET SIZE, GROWTH RATE, AND FORECAST
3 PREMIUM INSIGHTS
3.1 ATTRACTIVE OPPORTUNITIES FOR PLAYERS IN VETERINARY PHARMACEUTICALS MARKET
3.2 ASIA PACIFIC: VETERINARY PHARMACEUTICALS MARKET, BY PRODUCT TYPE AND COUNTRY
3.3 VETERINARY PHARMACEUTICALS MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES
3.4 VETERINARY PHARMACEUTICALS MARKET: DEVELOPING VS. DEVELOPED ECONOMIES, 2026?2031
4 MARKET OVERVIEW
4.1 INTRODUCTION
4.2 MARKET DYNAMICS
4.2.1 DRIVERS
4.2.1.1 Rising companion animal ownership and pet humanization
4.2.1.2 Growing prevalence of infectious and dermatological diseases in animals
4.2.1.3 Increasing demand for animal-derived food products
4.2.2 RESTRAINTS
4.2.2.1 Growing concerns over antimicrobial resistance (AMR)
4.2.2.2 Stringent regulatory approval processes for veterinary drugs
4.2.3 OPPORTUNITIES
4.2.3.1 Rising demand for parasiticides and dermatology products
4.2.3.2 Growth potential in rural and low-income regions
4.2.4 CHALLENGES
4.2.4.1 Monitoring drug residues in food-producing animals
4.2.4.2 Balancing animal welfare, productivity, and compliance requirements
4.3 UNMET NEEDS AND WHITE SPACES
4.4 INTERCONNECTED MARKET AND CROSS-SECTOR OPPORTUNITIES
4.4.1 INTERCONNECTED MARKETS
4.4.2 CROSS-SECTOR OPPORTUNITIES
4.5 STRATEGIC MOVES BY TIER-1/2/3 PLAYERS
5 INDUSTRY TRENDS
5.1 PORTER’S FIVE FORCES ANALYSIS
5.1.1 THREAT OF NEW ENTRANTS
5.1.2 THREAT OF SUBSTITUTES
5.1.3 BARGAINING POWER OF SUPPLIERS
5.1.4 BARGAINING POWER OF BUYERS
5.1.5 INTENSITY OF COMPETITIVE RIVALRY
5.2 MACROECONOMICS INDICATORS
5.2.1 INTRODUCTION
5.2.2 GDP TRENDS AND FORECAST
5.2.3 TRENDS IN GLOBAL ANIMAL HEALTHCARE INDUSTRY
5.2.4 TRENDS IN GLOBAL VETERINARY PHARMACEUTICALS INDUSTRY
5.3 VALUE CHAIN ANALYSIS
5.4 SUPPLY CHAIN ANALYSIS
5.5 ECOSYSTEM ANALYSIS
5.6 PRICING ANALYSIS
5.6.1 AVERAGE SELLING PRICE TREND OF PRODUCTS, BY KEY PLAYERS, 2023–2025
5.6.2 AVERAGE SELLING PRICE TREND OF FORMULATION TYPES, BY KEY PLAYERS, 2023–2025
5.6.3 AVERAGE SELLING PRICE TREND OF PRODUCTS, BY REGION, 2023–2025
5.7 TRADE ANALYSIS
5.7.1 IMPORT DATA FOR HS CODE 30, 2021–2024
5.7.1.1 Import scenario (HS code 30)
5.7.2 EXPORT DATA FOR HS CODE 30, 2021–2024
5.7.3 EXPORT SCENARIO (HS CODE 30)
5.8 KEY CONFERENCES AND EVENTS IN 2026–2027
5.9 TRENDS/DISRUPTIONS IMPACTING CUSTOMER BUSINESS
5.10 INVESTMENT AND FUNDING SCENARIO
5.11 CASE STUDY ANALYSIS
5.11.1 ZOETIS INC.
5.11.2 BOEHRINGER INGELHEIM ANIMAL HEALTH
5.11.3 MERCK ANIMAL HEALTH
5.11.4 ELANCO ANIMAL HEALTH
5.11.5 CEVA SANTE ANIMALE
5.12 IMPACT OF 2025 US TARIFF - VETERINARY PHARMACEUTICALS MARKET
5.12.1 INTRODUCTION
5.12.2 KEY TARIFF RATES
5.12.3 PRICE IMPACT ANALYSIS
5.12.4 IMPACT ON REGIONS
5.12.4.1 North America
5.12.4.2 Europe
5.12.4.3 Asia Pacific
5.12.5 IMPACT ON END-USE INDUSTRIES
5.12.5.1 Veterinary hospitals & clinics
5.12.5.2 Home care settings
5.12.5.3 Livestock farms
5.12.5.4 Rescue centers & NGOs
5.12.5.5 Other end users
6 TECHNOLOGICAL ADVANCEMENTS, AI-DRIVEN IMPACT, PATENTS, INNOVATIONS, AND FUTURE APPLICATIONS
6.1 TECHNOLOGY ANALYSIS
6.1.1 KEY EMERGING TECHNOLOGIES
6.1.1.1 Controlled release formulation
6.1.1.2 Biologics and monoclonal antibodies
6.1.2 COMPLEMENTARY TECHNOLOGIES
6.1.2.1 Digital health and telemedicine platforms
6.1.2.2 Veterinary biomarker analysis
6.1.3 ADJACENT TECHNOLOGIES
6.1.3.1 Wearable animal health monitoring devices
6.1.3.2 Stem cell therapy and regenerative medicine
6.2 TECHNOLOGY/PRODUCT ROADMAP
6.3 PATENT ANALYSIS
6.3.1 PUBLICATION TRENDS FOR VETERINARY PHARMACEUTICALS
6.3.2 INSIGHTS ON PATENT PUBLICATION TRENDS, TOP APPLICANTS AND JURISDICTION FOR VETERINARY PHARMACEUTICALS MARKET, JANUARY 2015–DECEMBER 2025
6.3.3 LIST OF MAJOR PATENTS, 2023–2025
6.4 FUTURE APPLICATIONS
6.4.1 PRECISION LIVESTOCK HEALTH MANAGEMENT
6.4.2 ONCOLOGY AND CHRONIC DISEASE MANAGEMENT
6.4.3 REPRODUCTIVE AND FERTILITY ENHANCEMENT IN LIVESTOCK
6.4.4 INTEGRATED DISEASE SURVEILLANCE AND OUTBREAK CONTROL
6.5 IMPACT OF GEN AI ON VETERINARY PHARMACEUTICALS MARKET
7 REGULATORY LANDSCAPE AND SUSTAINABILITY INITIATIVES
7.1 REGIONAL REGULATIONS AND COMPLIANCE
7.1.1 REGULATORY FRAMEWORK
7.1.1.1 North America
7.1.1.2 Europe
7.1.2 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
7.1.3 INDUSTRY STANDARDS
7.1.3.1 VICH Guidelines (International Co-operation on Harmonisation of Technical Requirements for Registration of Veterinary Medicinal Products)
7.1.3.2 Good Manufacturing Practice (GMP) Standards – PIC/S Guide (PE 009 series)
7.1.3.3 Codex Alimentarius Standards for Veterinary Drug Residues (CXM 2 – Maximum Residue Limits)
7.2 SUSTAINABILITY INITIATIVES
7.2.1 ECO-FRIENDLY AND RECYCLABLE MATERIALS IN VETERINARY PHARMACEUTICALS MARKET
7.2.1.1 Virbac – Eco-pack to reduce single-use plastic in veterinary products
7.2.1.2 Boehringer Ingelheim Animal Health – Renewable energy-powered manufacturing
7.2.1.3 Boehringer Ingelheim – Recyclable veterinary delivery device (Aservo, EquiHaler)
7.3 CERTIFICATIONS, LABELING, ECO-STANDARDS
8 CUSTOMER LANDSCAPE AND BUYER BEHAVIOR
8.1 DECISION-MAKING PROCESS
8.2 KEY STAKEHOLDERS INVOLVED IN BUYING PROCESS AND THEIR EVALUATION CRITERIA
8.2.1 KEY STAKEHOLDERS IN BUYING PROCESS
8.2.2 BUYING CRITERIA
8.3 ADOPTION BARRIERS AND INTERNAL CHALLENGES
8.4 UNMET NEEDS IN VARIOUS END-USE SETTINGS
8.5 MARKET PROFITABILITY
8.5.1 PRODUCT INNOVATION AND DIFFERENTIATION
8.5.2 EXPANSION OF COMPANION ANIMAL HEALTHCARE SPENDING
8.5.3 OPERATIONAL SCALE AND DISTRIBUTION EFFICIENCY
9 VETERINARY PHARMACEUTICALS MARKET, BY PRODUCT TYPE
9.1 INTRODUCTION
9.1.1 VETERINARY PHARMACEUTICALS MARKET VOLUME ANALYSIS BY PRODUCT TYPE, 2024–2031 (THOUSAND UNITS)
9.2 DRUGS
9.2.1 ANTI-BACTERIAL DRUGS
9.2.1.1 Routine use in livestock and companion animals underpins strong market share and steady growth
9.2.2 ANTI-FUNGAL DRUGS
9.2.2.1 Limited approvals and off-label systemic use result in smaller but clinically essential segment
9.2.3 ANTI-VIRAL DRUGS
9.2.3.1 Low current penetration but rising research interest driven by outbreak response and targeted therapies
9.2.4 ANTI-INFLAMMATORY DRUGS
9.2.4.1 Rising surgical volumes and chronic pain management drive stable double-digit market share
9.2.5 ANTI-PARASITIC DRUGS
9.2.5.1 High parasitic burden and preventive care practices sustain market share and strong growth trajectory
9.2.6 ANTI-CANCER DRUGS
9.2.6.1 Increasing pet oncology awareness and advanced therapeutics to fuel growth from small base
9.2.7 CARDIOVASCULAR AND RENAL DRUGS
9.2.7.1 Rising diagnosis of chronic heart and kidney disorders supports steady mid-single-digit market share
9.2.8 GASTROINTESTINAL DRUGS
9.2.8.1 High incidence of digestive disorders and dietary transitions drive sustained demand
9.2.9 OTHER DRUGS
9.3 MONOCLONAL ANTIBODIES
9.3.1 TARGETED BIOLOGICS AND RISING COMPANION ANIMAL THERAPEUTICS TO DRIVE DEMAND
9.4 IMMUNOMODULATORS
9.4.1 INCREASING FOCUS ON IMMUNE-MEDIATED DISEASES AND PREVENTIVE HEALTH TO SUPPORT GRADUAL EXPANSION FROM SMALLER BASE
9.5 MEDICATED FEED ADDITIVES
9.5.1 AMINO ACIDS
9.5.1.1 Protein optimization and feed cost efficiency to drive demand
9.5.2 ENZYMES
9.5.2.1 Improved nutrient digestibility and cost optimization to support steady adoption
9.5.3 VITAMINS AND MINERALS
9.5.3.1 Essential micronutrient supplementation ensures largest market share
9.5.4 OTHER MEDICATED FEED ADDITIVES
10 VETERINARY PHARMACEUTICALS MARKET, BY ROUTE OF ADMINISTRATION
10.1 INTRODUCTION
10.2 ORAL
10.2.1 EASE OF DOSING AND HIGH COMPLIANCE IN COMPANION AND LIVESTOCK ANIMALS
10.3 PARENTERAL
10.3.1 RAPID THERAPEUTIC ACTION AND HIGHER BIOAVAILABILITY IN CRITICAL CARE AND PRODUCTION SETTINGS
10.4 TOPICAL
10.4.1 RISING DERMATOLOGY CASES AND DEMAND FOR LOCALIZED, NON-INVASIVE TREATMENTS
10.5 OTHER ROUTES OF ADMINISTRATION
11 VETERINARY PHARMACEUTICALS MARKET, BY FORMULATION TYPE
11.1 INTRODUCTION
11.2 SOLID
11.2.1 DOSING STABILITY, COST EFFICIENCY, AND EASE OF LARGE-SCALE ADMINISTRATION IN LIVESTOCK AND COMPANION ANIMALS
11.3 LIQUID
11.3.1 RAPID ABSORPTION, FLEXIBLE DOSING, AND SUITABILITY FOR INJECTABLES AND ORAL SUSPENSIONS
11.4 SEMI-SOLID
11.4.1 RISING DERMATOLOGY CASES AND INCREASING COMPANION ANIMAL CARE EXPENDITURE
11.5 AEROSOL/SPRAY
11.5.1 CONVENIENCE, TARGETED DELIVERY, AND REDUCED CROSS-CONTAMINATION RISK
11.6 PREMIX FORMULATIONS
11.6.1 DEMAND FOR MEDICATED FEED AND PREVENTIVE HERD-LEVEL DISEASE MANAGEMENT TO DRIVE MARKET
12 VETERINARY PHARMACEUTICALS MARKET, BY INDICATION
12.1 INTRODUCTION
12.2 INFECTIOUS DISEASES
12.2.1 ZOONOTIC RISK AND LIVESTOCK DISEASE CONTROL PROGRAMS TO DRIVE MARKET
12.3 DERMATOLOGICAL DISEASES
12.3.1 RISING CHRONIC SKIN CONDITIONS AND PREMIUM COMPANION ANIMAL SPENDING TO DRIVE MARKET
12.4 PAIN MANAGEMENT
12.4.1 RISING SURGICAL PROCEDURES AND AGING PET POPULATION TO DRIVE MARKET
12.5 CARDIOVASCULAR AND RENAL DISEASES
12.5.1 INCREASED DIAGNOSIS IN AGING COMPANION ANIMALS TO DRIVE MARKET
12.6 GASTROINTESTINAL DISEASES
12.6.1 HIGH PREVALENCE OF ENTERIC INFECTIONS AND DIETARY DISORDERS TO DRIVE MARKET
12.7 OTHER INDICATIONS
13 VETERINARY PHARMACEUTICALS MARKET, BY ANIMAL TYPE
13.1 INTRODUCTION
13.2 COMPANION ANIMALS
13.2.1 DOGS
13.2.1.1 Increasing population and adoption of dogs to drive market
13.2.2 CATS
13.2.2.1 Emerging trends in feline pharmaceuticals to boost market
13.2.3 HORSES
13.2.3.1 Higher risk of traumatic injuries in horses to drive demand for veterinary pharmaceutical products
13.2.4 OTHER COMPANION ANIMALS
13.3 LIVESTOCK ANIMALS
13.3.1 CATTLE
13.3.1.1 Economic importance of dairy and beef cattle to drive growth
13.3.2 SWINE
13.3.2.1 Growing surgical volume for acute conditions in swine to drive market
13.3.3 POULTRY
13.3.3.1 Growing focus on infection prevention and flock health management to drive market
13.3.4 OTHER LIVESTOCK ANIMALS
14 VETERINARY PHARMACEUTICALS MARKET, BY DISTRIBUTION CHANNEL
14.1 INTRODUCTION
14.2 VETERINARY HOSPITAL PHARMACIES
14.2.1 HIGH IMPORTANCE AND BETTER OPPORTUNITIES IN ON-FARM VETERINARY PHARMACEUTICALS TO DRIVE MARKET
14.3 RETAIL PHARMACIES
14.3.1 RETAIL PHARMACIES TO AID ACCESSIBILITY AND MARKET REACH IN VETERINARY PHARMACEUTICALS
14.4 ONLINE PHARMACIES
14.4.1 CONVENIENCE AND ACCESSIBILITY TO AUGMENT MARKET GROWTH
14.5 DIRECT SALES
14.5.1 DIRECT SALES TO STRENGTHEN MANUFACTURER-TO-CUSTOMER CONNECTIONS
15 VETERINARY PHARMACEUTICALS MARKET, BY END USER
15.1 INTRODUCTION
15.2 VETERINARY HOSPITALS & CLINICS
15.2.1 FIRST POINT OF CONTACT FOR ANIMAL OWNERS AND LIVESTOCK CAREGIVERS
15.3 LIVESTOCK FARMS
15.3.1 GROWING IMPORTANCE AND OPPORTUNITIES IN ON-FARM ANIMAL CARE
15.4 HOME CARE SETTINGS
15.4.1 RISING PET EXPENDITURE TO PROPEL SEGMENT GROWTH
15.5 OTHER END USERS
16 VETERINARY PHARMACEUTICALS MARKET, BY REGION
16.1 INTRODUCTION
16.2 NORTH AMERICA
16.2.1 MACROECONOMIC OUTLOOK FOR NORTH AMERICA
16.2.2 NORTH AMERICA: VETERINARY PHARMACEUTICALS MARKET VOLUME ANALYSIS BY PRODUCT TYPE, 2024–2031 (THOUSAND UNITS)
16.2.3 US
16.2.3.1 Surge in animal healthcare expenditure to boost market
16.2.4 CANADA
16.2.4.1 Growing pet population and advanced veterinary services to drive market
16.3 EUROPE
16.3.1 MACROECONOMIC OUTLOOK FOR EUROPE
16.3.2 EUROPE: VETERINARY PHARMACEUTICALS MARKET VOLUME ANALYSIS BY PRODUCT TYPE, 2024–2031 (THOUSAND UNITS)
16.3.3 GERMANY
16.3.3.1 Increased focus on animal welfare to drive demand for veterinary pharmaceutical products
16.3.4 UK
16.3.4.1 Increasing pet ownership to propel market
16.3.5 FRANCE
16.3.5.1 High standards of veterinary care to provide attractive growth opportunities for market players
16.3.6 ITALY
16.3.6.1 Growing pet owner awareness and increasing livestock population to drive market
16.3.7 SPAIN
16.3.7.1 Increasing awareness of animal health to drive market
16.3.8 REST OF EUROPE
16.4 ASIA PACIFIC
16.4.1 MACROECONOMIC OUTLOOK FOR ASIA PACIFIC
16.4.2 ASIA PACIFIC: VETERINARY PHARMACEUTICALS MARKET VOLUME ANALYSIS BY PRODUCT TYPE, 2024–2031 (THOUSAND UNITS)
16.4.3 JAPAN
16.4.3.1 Surge in pet care expenditure and growing adoption of companion animals to drive market
16.4.4 CHINA
16.4.4.1 Increasing animal healthcare expenditure and advancements in veterinary medicines to drive market
16.4.5 INDIA
16.4.5.1 Increasing livestock population to propel market growth
16.4.6 AUSTRALIA
16.4.6.1 Growing companion animal ownership and rise in animal health awareness to support market growth
16.4.7 SOUTH KOREA
16.4.7.1 Growing pet ownership and advancements in veterinary medicine to favor market growth
16.4.8 PHILIPPINES
16.4.8.1 Tourism-linked pet culture and veterinary advancements to fuel market
16.4.9 REST OF ASIA PACIFIC
16.5 LATIN AMERICA
16.5.1 MACROECONOMIC OUTLOOK FOR LATIN AMERICA
16.5.2 LATIN AMERICA: VETERINARY PHARMACEUTICALS MARKET VOLUME ANALYSIS BY PRODUCT TYPE, 2024–2031 (THOUSAND UNITS)
16.5.3 BRAZIL
16.5.3.1 Growing pet population and rising disposable incomes to drive market
16.5.4 MEXICO
16.5.4.1 Robust livestock base and growing companion animal care to drive market
16.5.5 REST OF LATIN AMERICA
16.6 MIDDLE EAST & AFRICA
16.6.1 MACROECONOMIC OUTLOOK FOR MIDDLE EAST & AFRICA
16.6.2 MIDDLE EAST & AFRICA: VETERINARY PHARMACEUTICALS MARKET VOLUME ANALYSIS BY PRODUCT TYPE, 2024–2031 (THOUSAND UNITS)
16.7 GCC COUNTRIES
16.7.1 KINGDOM OF SAUDI ARABIA (KSA)
16.7.1.1 Vision 2030 investments to drive market
16.7.2 UNITED ARAB EMIRATES (UAE)
16.7.2.1 Increasing adoption of advanced diagnostic technologies to contribute to market growth
16.7.3 REST OF GCC COUNTRIES
16.7.4 REST OF MIDDLE EAST & AFRICA
17 COMPETITIVE LANDSCAPE
17.1 INTRODUCTION
17.1.1 KEY PLAYER COMPETITIVE STRATEGIES/RIGHT TO WIN, 2023–2026
17.2 REVENUE ANALYSIS, 2023–2025
17.3 MARKET SHARE ANALYSIS, 2025
17.3.1 US: VETERINARY PHARMACEUTICALS MARKET SHARE ANALYSIS, 2025
17.3.2 EUROPE: VETERINARY PHARMACEUTICALS MARKET SHARE ANALYSIS, 2025
17.4 PRODUCT/BRAND COMPARISON
17.5 COMPANY EVALUATION MATRIX: KEY PLAYERS, 2025
17.5.1 STARS
17.5.2 EMERGING LEADERS
17.5.3 PERVASIVE PLAYERS
17.5.4 PARTICIPANTS
17.5.5 COMPANY FOOTPRINT: KEY PLAYERS, 2025
17.5.5.1 Company footprint
17.5.5.2 Region footprint
17.5.5.3 Product type footprint
17.5.5.4 Route of administration footprint
17.5.5.5 Indication footprint
17.5.5.6 End user footprint
17.6 COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2025
17.6.1 PROGRESSIVE COMPANIES
17.6.2 RESPONSIVE COMPANIES
17.6.3 DYNAMIC COMPANIES
17.6.4 STARTING BLOCKS
17.6.5 COMPETITIVE BENCHMARKING: STARTUPS/SMES, 2025
17.6.5.1 Detailed list of key startups/SMEs
17.6.5.2 Competitive benchmarking of key startups/SMEs
17.7 COMPANY VALUATION AND FINANCIAL METRICS
17.8 COMPETITIVE SCENARIO
17.8.1 PRODUCT LAUNCHES & APPROVALS
17.8.2 DEALS
17.8.3 EXPANSIONS
17.8.4 OTHER DEVELOPMENTS
18 COMPANY PROFILES
18.1 KEY PLAYERS
18.1.1 ZOETIS INC.
18.1.1.1 Business overview
18.1.1.2 Products offered
18.1.1.3 Recent developments
18.1.1.3.1 Product launches & approvals
18.1.1.3.2 Expansions
18.1.1.3.3 Other developments
18.1.1.4 MnM view
18.1.1.4.1 Right to win
18.1.1.4.2 Strategic choices
18.1.1.4.3 Weaknesses and competitive threats
18.1.2 MERCK & CO., INC
18.1.2.1 Business overview
18.1.2.2 Products offered
18.1.2.3 Recent developments
18.1.2.3.1 Product launches & approvals
18.1.2.3.2 Deals
18.1.2.3.3 Expansions
18.1.2.4 MnM view
18.1.2.4.1 Right to win
18.1.2.4.2 Strategic choices
18.1.2.4.3 Weaknesses and competitive threats
18.1.3 BOEHRINGER INGELHEIM INTERNATIONAL GMBH
18.1.3.1 Business overview
18.1.3.2 Products offered
18.1.3.3 Recent developments
18.1.3.3.1 Product launches & approvals
18.1.3.3.2 Deals
18.1.3.3.3 Expansions
18.1.3.4 MnM view
18.1.3.4.1 Right to win
18.1.3.4.2 Strategic choices
18.1.3.4.3 Weaknesses and competitive threats
18.1.4 ELANCO ANIMAL HEALTH INCORPORATED
18.1.4.1 Business overview
18.1.4.2 Products offered
18.1.4.3 Recent developments
18.1.4.3.1 Product launches & approvals
18.1.4.3.2 Expansions
18.1.4.3.3 Other developments
18.1.4.4 MnM view
18.1.4.4.1 Right to win
18.1.4.4.2 Strategic choices
18.1.4.4.3 Weaknesses and competitive threats
18.1.5 VIRBAC
18.1.5.1 Business overview
18.1.5.2 Products offered
18.1.5.3 Recent developments
18.1.5.3.1 Product launches & approvals
18.1.5.3.2 Deal
18.1.5.3.3 Expansions
18.1.5.4 MnM view
18.1.5.4.1 Right to win
18.1.5.4.2 Strategic choices
18.1.5.4.3 Weaknesses and competitive threats
18.1.6 CEVA
18.1.6.1 Business overview
18.1.6.2 Products offered
18.1.6.3 Recent developments
18.1.6.3.1 Deals
18.1.6.3.2 Expansions
18.1.7 VETOQUINOL
18.1.7.1 Business overview
18.1.7.2 Products offered
18.1.7.3 Recent developments
18.1.7.3.1 Product launches & approvals
18.1.7.3.2 Deals
18.1.8 DECHRA PHARMACEUTICALS PLC
18.1.8.1 Business overview
18.1.8.2 Products offered
18.1.8.3 Recent developments
18.1.8.3.1 Product launches & approvals
18.1.8.3.2 Deals
18.1.8.3.3 Other developments
18.1.9 NORBROOK
18.1.9.1 Business overview
18.1.9.2 Products offered
18.1.9.3 Recent developments
18.1.9.3.1 Product launches & approvals
18.1.9.3.2 Deals
18.1.9.3.3 Expansions
18.1.9.3.4 Other developments
18.1.10 BIMEDA CORPORATE
18.1.10.1 Business overview
18.1.10.2 Products offered
18.1.10.3 Recent developments
18.1.10.3.1 Product launches & approvals
18.1.10.3.2 Deals
18.1.10.3.3 Expansions
18.1.11 HESTER BIOSCIENCES LIMITED
18.1.11.1 Business overview
18.1.11.2 Products offered
18.1.12 INDIAN IMMUNOLOGICALS LTD.
18.1.12.1 Business overview
18.1.12.2 Products offered
18.1.13 ANIMALCARE GROUP PLC
18.1.13.1 Business overview
18.1.13.2 Products offered
18.1.13.3 Recent developments
18.1.13.3.1 Deals
18.1.13.3.2 Product launches & approvals
18.1.14 KYORITSU SEIYAKU CORPORATION
18.1.14.1 Business overview
18.1.14.2 Products offered
18.1.14.3 Recent developments
18.1.14.3.1 Product launches & approvals
18.1.14.3.2 Deals
18.1.15 CALIER
18.1.15.1 Business overview
18.1.15.2 Products offered
18.1.15.3 Recent developments
18.1.15.3.1 Product launches & approvals
18.2 OTHER PLAYERS
18.2.1 DOPHARMA
18.2.2 PHARMGATE ANIMAL HEALTH
18.2.3 BIOVETA, A.S.
18.2.4 NEXTMUNE
18.2.5 TRIVIUMVET
18.2.6 DOMES PHARMA
18.2.7 UNIVET LIMITED
18.2.8 CENAVISA, S.L.
18.2.9 FATRO S.P.A.
18.2.10 CHANELLE PHARMA
19 RESEARCH METHODOLOGY
19.1 RESEARCH DATA
19.1.1 SECONDARY DATA
19.1.1.1 Key data from secondary sources
19.1.2 PRIMARY DATA
19.1.2.1 Key data from primary sources
19.1.2.2 Key industry insights
19.1.2.3 Key industry insights
19.2 MARKET SIZE ESTIMATION
19.3 GROWTH FORECAST
19.3.1 KEY INDUSTRY INSIGHTS
19.4 MARKET BREAKDOWN AND DATA TRIANGULATION
19.5 RESEARCH ASSUMPTIONS
19.6 RESEARCH LIMITATIONS
19.7 RISK ASSESSMENT
20 APPENDIX
20.1 DISCUSSION GUIDE
20.2 KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL
20.3 CUSTOMIZATION OPTIONS
20.3.1 PRODUCT ANALYSIS
20.3.2 US END USER ANALYSIS
20.3.3 GEOGRAPHIC ANALYSIS
20.3.4 COMPANY INFORMATION
20.3.5 REGIONAL/COUNTRY LEVEL MARKET SHARE ANALYSIS
20.3.6 COUNTRY LEVEL VOLUME ANALYSIS BY PRODUCT TYPE
20.3.7 BY PRODUCT TYPE MARKET SHARE ANALYSIS (TOP 5 PLAYERS)
20.3.8 ANY CONSULTS/CUSTOM REQUIREMENTS AS PER CLIENT REQUEST
20.4 RELATED REPORTS
20.5 AUTHOR DETAILS
LIST OF TABLES
TABLE 1 STANDARD CURRENCY CONVERSION RATES (UNIT OF USD)
TABLE 2 PET (DOGS AND CATS) OWNERSHIP STATISTICS IN US, 2024
TABLE 3 COMPANION ANIMAL POPULATION STATISTICS, BY REGION
TABLE 4 RECENT GOVERNMENT-REPORTED INDICATORS
TABLE 5 TRENDS IN CONSUMPTION OF MEAT & MILK IN DEVELOPED & EMERGING ECONOMIES
TABLE 6 ASIA: COUNTRY-LEVEL CONSUMPTION OF ANIMAL-DERIVED FOOD PRODUCTS, 2020 VS. 2030 (THOUSAND METRIC TONS)
TABLE 7 ASIA: COUNTRY-LEVEL PRODUCTION OF ANIMAL-DERIVED FOOD PRODUCTS, 2020 VS. 2030 (THOUSAND METRIC TONS)
TABLE 8 UNMET CUSTOMER NEEDS AND WHITE SPACES IN VETERINARY PHARMACEUTICALS MARKET.
TABLE 9 INTERCONNECTED MARKETS IN VETERINARY PHARMACEUTICALS MARKET
TABLE 10 CROSS-SECTOR MARKETS IN VETERINARY PHARMACEUTICALS MARKET
TABLE 11 STRATEGIC MOVES BY TIER-1/2/3 PLAYERS
TABLE 12 IMPACT OF PORTER’S FIVE FORCES ON VETERINARY PHARMACEUTICALS MARKET
TABLE 13 GDP TREND AND FORECAST, BY COUNTRY, 2021–2030 (USD BILLION)
TABLE 14 AVERAGE SELLING PRICE TREND OF PRODUCTS, BY KEY PLAYERS, 2023–2025
TABLE 15 AVERAGE SELLING PRICE TREND OF FORMULATION TYPES, BY KEY PLAYERS, 2023–2025
TABLE 16 AVERAGE SELLING PRICE TREND OF PRODUCTS, BY REGION, 2023–2025
TABLE 17 IMPORT DATA FOR HS CODE 30, BY COUNTRY, 2021–2024 (USD MILLION)
TABLE 18 EXPORT DATA FOR HS CODE 30, BY COUNTRY, 2021–2024 (USD MILLION)
TABLE 19 DETAILED LIST OF CONFERENCES AND EVENTS, 2026–2027
TABLE 20 US ADJUSTED RECIPROCAL TARIFF RATES
TABLE 21 TECHNOLOGY/PRODUCT ROADMAP
TABLE 22 VETERINARY PHARMACEUTICALS MARKET: LIST OF MAJOR PATENTS, JANUARY 2023–DECEMBER 2025
TABLE 23 NORTH AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
TABLE 24 EUROPE: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
TABLE 25 ASIA PACIFIC: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
TABLE 26 REST OF THE WORLD: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
TABLE 27 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS FOR VETERINARY PHARMACEUTICAL PRODUCTS
TABLE 28 KEY BUYING CRITERIA FOR TOP THREE END USERS
TABLE 29 VETERINARY PHARMACEUTICALS MARKET: UNMET NEEDS IN KEY END-USE SETTINGS
TABLE 30 VETERINARY PHARMACEUTICALS MARKET, BY PRODUCT TYPE, 2024–2031 (THOUSAND UNITS)
TABLE 31 VETERINARY PHARMACEUTICALS MARKET, BY PRODUCT TYPE, 2024–2031 (USD MILLION)
TABLE 32 VETERINARY PHARMACEUTICALS MARKET FOR DRUGS, BY TYPE, 2024–2031 (USD MILLION)
TABLE 33 VETERINARY PHARMACEUTICALS MARKET FOR DRUGS, BY COUNTRY/REGION, 2024–2031 (USD MILLION)
TABLE 34 VETERINARY PHARMACEUTICALS MARKET FOR ANTI-BACTERIAL DRUGS, BY COUNTRY/REGION, 2024–2031 (USD MILLION)
TABLE 35 VETERINARY PHARMACEUTICALS MARKET FOR ANTI-FUNGAL DRUGS, BY COUNTRY/REGION, 2024–2031 (USD MILLION)
TABLE 36 VETERINARY PHARMACEUTICALS MARKET FOR ANTI-VIRAL DRUGS, BY COUNTRY/REGION, 2024–2031 (USD MILLION)
TABLE 37 VETERINARY PHARMACEUTICALS MARKET FOR ANTI-INFLAMMATORY DRUGS, BY COUNTRY/REGION, 2024–2031 (USD MILLION)
TABLE 38 VETERINARY PHARMACEUTICALS MARKET FOR ANTI-PARASITIC DRUGS, BY COUNTRY/REGION, 2024–2031 (USD MILLION)
TABLE 39 VETERINARY PHARMACEUTICALS MARKET FOR ANTI-CANCER DRUGS, BY COUNTRY/REGION, 2024–2031 (USD MILLION)
TABLE 40 VETERINARY PHARMACEUTICALS MARKET FOR CARDIOVASCULAR AND RENAL DRUGS, BY COUNTRY/REGION, 2024–2031 (USD MILLION)
TABLE 41 VETERINARY PHARMACEUTICALS MARKET FOR GASTROINTESTINAL DRUGS, BY COUNTRY/REGION, 2024–2031 (USD MILLION)
TABLE 42 VETERINARY PHARMACEUTICALS MARKET FOR OTHER DRUGS, BY COUNTRY/REGION, 2024–2031 (USD MILLION)
TABLE 43 VETERINARY PHARMACEUTICALS MARKET FOR MONOCLONAL ANTIBODIES, BY COUNTRY/REGION, 2024–2031 (USD MILLION)
TABLE 44 VETERINARY PHARMACEUTICALS MARKET FOR IMMUNOMODULATORS, BY COUNTRY/REGION, 2024–2031 (USD MILLION)
TABLE 45 VETERINARY PHARMACEUTICALS MARKET FOR MEDICATED FEED ADDITIVES, BY TYPE, 2024–2031 (USD MILLION)
TABLE 46 VETERINARY PHARMACEUTICALS MARKET FOR MEDICATED FEED ADDITIVES, BY COUNTRY/REGION, 2024–2031 (USD MILLION)
TABLE 47 VETERINARY PHARMACEUTICALS MARKET FOR AMINO ACIDS, BY COUNTRY/REGION, 2024–2031 (USD MILLION)
TABLE 48 VETERINARY PHARMACEUTICALS MARKET FOR ENZYMES, BY COUNTRY/REGION, 2024–2031 (USD MILLION)
TABLE 49 VETERINARY PHARMACEUTICALS MARKET FOR VITAMINS AND MINERALS, BY COUNTRY/REGION, 2024–2031 (USD MILLION)
TABLE 50 VETERINARY PHARMACEUTICALS MARKET FOR OTHER MEDICATED FEED ADDITIVES, BY COUNTRY/REGION, 2024–2031 (USD MILLION)
TABLE 51 VETERINARY PHARMACEUTICALS MARKET, BY ROUTE OF ADMINISTRATION, 2024–2031 (USD MILLION)
TABLE 52 VETERINARY PHARMACEUTICALS MARKET FOR ORAL, BY COUNTRY/REGION, 2024–2031 (USD MILLION)
TABLE 53 VETERINARY PHARMACEUTICALS MARKET FOR PARENTERAL, BY COUNTRY/REGION, 2024–2031 (USD MILLION)
TABLE 54 VETERINARY PHARMACEUTICALS MARKET FOR TOPICAL, BY COUNTRY/REGION, 2024–2031 (USD MILLION)
TABLE 55 VETERINARY PHARMACEUTICALS MARKET FOR OTHER ROUTES OF ADMINISTRATION, BY COUNTRY/REGION, 2024–2031 (USD MILLION)
TABLE 56 VETERINARY PHARMACEUTICALS MARKET, BY FORMULATION TYPE, 2024–2031 (USD MILLION)
TABLE 57 VETERINARY PHARMACEUTICALS MARKET FOR SOLID, BY COUNTRY/REGION, 2024–2031 (USD MILLION)
TABLE 58 VETERINARY PHARMACEUTICALS MARKET FOR LIQUID, BY COUNTRY/REGION, 2024–2031 (USD MILLION)
TABLE 59 VETERINARY PHARMACEUTICALS MARKET FOR SEMI-SOLID, BY COUNTRY/REGION, 2024–2031 (USD MILLION)
TABLE 60 VETERINARY PHARMACEUTICALS MARKET FOR AEROSOL/SPRAY, BY COUNTRY/REGION, 2024–2031 (USD MILLION)
TABLE 61 VETERINARY PHARMACEUTICALS MARKET FOR PREMIX FORMULATIONS, BY COUNTRY/REGION, 2024–2031 (USD MILLION)
TABLE 62 VETERINARY PHARMACEUTICALS MARKET, BY INDICATION, 2024–2031 (USD MILLION)
TABLE 63 VETERINARY PHARMACEUTICALS MARKET FOR INFECTIOUS DISEASES, BY COUNTRY/REGION, 2024–2031 (USD MILLION)
TABLE 64 VETERINARY PHARMACEUTICALS MARKET FOR DERMATOLOGICAL DISEASES, BY COUNTRY/REGION, 2024–2031 (USD MILLION)
TABLE 65 VETERINARY PHARMACEUTICALS MARKET FOR PAIN MANAGEMENT, BY COUNTRY/REGION, 2024–2031 (USD MILLION)
TABLE 66 VETERINARY PHARMACEUTICALS MARKET FOR CARDIOVASCULAR AND RENAL DISEASES, BY COUNTRY/REGION, 2024–2031 (USD MILLION)
TABLE 67 VETERINARY PHARMACEUTICALS MARKET FOR GASTROINTESTINAL DISEASES, BY COUNTRY/REGION, 2024–2031 (USD MILLION)
TABLE 68 VETERINARY PHARMACEUTICALS MARKET FOR OTHER INDICATIONS, BY COUNTRY/REGION, 2024–2031 (USD MILLION)
TABLE 69 VETERINARY PHARMACEUTICALS MARKET, BY ANIMAL TYPE, 2024–2031 (USD MILLION)
TABLE 70 VETERINARY PHARMACEUTICALS MARKET FOR COMPANION ANIMALS, BY TYPE, 2024–2031 (USD MILLION)
TABLE 71 VETERINARY PHARMACEUTICALS MARKET FOR COMPANION ANIMALS, BY COUNTRY/REGION, 2024–2031 (USD MILLION)
TABLE 72 VETERINARY PHARMACEUTICALS MARKET FOR DOGS, BY COUNTRY/REGION, 2024–2031 (USD MILLION)
TABLE 73 VETERINARY PHARMACEUTICALS MARKET FOR CATS, BY COUNTRY/REGION, 2024–2031 (USD MILLION)
TABLE 74 VETERINARY PHARMACEUTICALS MARKET FOR HORSES, BY COUNTRY/REGION, 2024–2031 (USD MILLION)
TABLE 75 VETERINARY PHARMACEUTICALS MARKET FOR OTHER COMPANION ANIMALS, BY COUNTRY/REGION, 2024–2031 (USD MILLION)
TABLE 76 VETERINARY PHARMACEUTICALS MARKET FOR LIVESTOCK ANIMALS, BY TYPE, 2024–2031 (USD MILLION)
TABLE 77 VETERINARY PHARMACEUTICALS MARKET FOR LIVESTOCK ANIMALS, BY COUNTRY/REGION, 2024–2031 (USD MILLION)
TABLE 78 VETERINARY PHARMACEUTICALS MARKET FOR CATTLE, BY COUNTRY/ REGION, 2024–2031 (USD MILLION)
TABLE 79 VETERINARY PHARMACEUTICALS MARKET FOR SWINE, BY COUNTRY/REGION, 2024–2031 (USD MILLION)
TABLE 80 VETERINARY PHARMACEUTICALS MARKET FOR POULTRY, BY COUNTRY/REGION, 2024–2031 (USD MILLION)
TABLE 81 VETERINARY PHARMACEUTICALS MARKET FOR OTHER LIVESTOCK ANIMALS, BY COUNTRY/REGION, 2024–2031 (USD MILLION)
TABLE 82 VETERINARY PHARMACEUTICALS MARKET, BY DISTRIBUTION CHANNEL, 2024–2031 (USD MILLION)
TABLE 83 VETERINARY PHARMACEUTICALS MARKET FOR VETERINARY HOSPITAL PHARMACIES, BY COUNTRY/REGION, 2024–2031 (USD MILLION)
TABLE 84 VETERINARY PHARMACEUTICALS MARKET FOR RETAIL PHARMACIES, BY COUNTRY/REGION, 2024–2031 (USD MILLION)
TABLE 85 VETERINARY PHARMACEUTICALS MARKET FOR ONLINE PHARMACIES, BY COUNTRY/REGION, 2024–2031 (USD MILLION)
TABLE 86 VETERINARY PHARMACEUTICALS MARKET FOR DIRECT SALES, BY COUNTRY/REGION, 2024–2031 (USD MILLION)
TABLE 87 VETERINARY PHARMACEUTICALS MARKET, BY END USER, 2024–2031 (USD MILLION)
TABLE 88 VETERINARY PHARMACEUTICALS MARKET FOR VETERINARY HOSPITALS & CLINICS, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 89 VETERINARY PHARMACEUTICALS MARKET FOR LIVESTOCK FARMS, BY COUNTRY/REGION, 2024–2031 (USD MILLION)
TABLE 90 VETERINARY PHARMACEUTICALS MARKET FOR HOME CARE SETTINGS, BY COUNTRY/REGION, 2024–2031 (USD MILLION)
TABLE 91 VETERINARY PHARMACEUTICALS MARKET FOR OTHER END USERS, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 92 VETERINARY PHARMACEUTICALS MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 93 VETERINARY PHARMACEUTICALS MARKET, BY COUNTRY/REGION, 2024–2031 (USD MILLION)
TABLE 94 NORTH AMERICA: VETERINARY PHARMACEUTICALS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 95 NORTH AMERICA: VETERINARY PHARMACEUTICALS MARKET, BY PRODUCT TYPE, 2024–2031 (USD MILLION)
TABLE 96 NORTH AMERICA: VETERINARY PHARMACEUTICALS MARKET, BY PRODUCT TYPE, 2024–2031 (THOUSAND UNITS)
TABLE 97 NORTH AMERICA: VETERINARY PHARMACEUTICALS MARKET FOR DRUGS, BY TYPE, 2024–2031 (USD MILLION)
TABLE 98 NORTH AMERICA: VETERINARY PHARMACEUTICALS MARKET FOR MEDICATED FEED ADDITIVES, BY TYPE, 2024–2031 (USD MILLION)
TABLE 99 NORTH AMERICA: VETERINARY PHARMACEUTICALS MARKET, BY ROUTE OF ADMINISTRATION, 2024–2031 (USD MILLION)
TABLE 100 NORTH AMERICA: VETERINARY PHARMACEUTICALS MARKET, BY FORMULATION TYPE, 2024–2031 (USD MILLION)
TABLE 101 NORTH AMERICA: VETERINARY PHARMACEUTICALS MARKET, BY INDICATION, 2024–2031 (USD MILLION)
TABLE 102 NORTH AMERICA: VETERINARY PHARMACEUTICALS MARKET, BY ANIMAL TYPE, 2024–2031 (USD MILLION)
TABLE 103 NORTH AMERICA: VETERINARY PHARMACEUTICALS MARKET FOR COMPANION ANIMALS, BY TYPE, 2024–2031 (USD MILLION)
TABLE 104 NORTH AMERICA: VETERINARY PHARMACEUTICALS MARKET FOR LIVESTOCK ANIMALS, BY TYPE, 2024–2031 (USD MILLION)
TABLE 105 NORTH AMERICA: VETERINARY PHARMACEUTICALS MARKET, BY DISTRIBUTION CHANNEL, 2024–2031 (USD MILLION)
TABLE 106 NORTH AMERICA: VETERINARY PHARMACEUTICALS MARKET, BY END USER, 2024–2031 (USD MILLION)
TABLE 107 US: KEY MACRO INDICATORS
TABLE 108 US: VETERINARY PHARMACEUTICALS MARKET, BY PRODUCT TYPE, 2024–2031 (USD MILLION)
TABLE 109 US: VETERINARY PHARMACEUTICALS MARKET FOR DRUGS, BY TYPE, 2024–2031 (USD MILLION)
TABLE 110 US: VETERINARY PHARMACEUTICALS MARKET FOR MEDICATED FEED ADDITIVES, BY TYPE, 2024–2031 (USD MILLION)
TABLE 111 US: VETERINARY PHARMACEUTICALS MARKET, BY ROUTE OF ADMINISTRATION, 2024–2031 (USD MILLION)
TABLE 112 US: VETERINARY PHARMACEUTICALS MARKET, BY FORMULATION TYPE, 2024–2031 (USD MILLION)
TABLE 113 US: VETERINARY PHARMACEUTICALS MARKET, BY INDICATION, 2024–2031 (USD MILLION)
TABLE 114 US: VETERINARY PHARMACEUTICALS MARKET, BY ANIMAL TYPE, 2024–2031 (USD MILLION)
TABLE 115 US: VETERINARY PHARMACEUTICALS MARKET FOR COMPANION ANIMALS, BY TYPE, 2024–2031 (USD MILLION)
TABLE 116 US: VETERINARY PHARMACEUTICALS MARKET FOR LIVESTOCK ANIMALS, BY TYPE, 2024–2031 (USD MILLION)
TABLE 117 US: VETERINARY PHARMACEUTICALS MARKET, BY DISTRIBUTION CHANNEL, 2024–2031 (USD MILLION)
TABLE 118 US: VETERINARY PHARMACEUTICALS MARKET, BY END USER, 2024–2031 (USD MILLION)
TABLE 119 CANADA: KEY MACRO INDICATORS
TABLE 120 CANADA: VETERINARY PHARMACEUTICALS MARKET, BY PRODUCT TYPE, 2024–2031 (USD MILLION)
TABLE 121 CANADA: VETERINARY PHARMACEUTICALS MARKET FOR DRUGS, BY TYPE, 2024–2031 (USD MILLION)
TABLE 122 CANADA: VETERINARY PHARMACEUTICALS MARKET FOR MEDICATED FEED ADDITIVES, BY TYPE, 2024–2031 (USD MILLION)
TABLE 123 CANADA: VETERINARY PHARMACEUTICALS MARKET, BY ROUTE OF ADMINISTRATION, 2024–2031 (USD MILLION)
TABLE 124 CANADA: VETERINARY PHARMACEUTICALS MARKET, BY FORMULATION TYPE, 2024–2031 (USD MILLION)
TABLE 125 CANADA: VETERINARY PHARMACEUTICALS MARKET, BY INDICATION, 2024–2031 (USD MILLION)
TABLE 126 CANADA: VETERINARY PHARMACEUTICALS MARKET, BY ANIMAL TYPE, 2024–2031 (USD MILLION)
TABLE 127 CANADA: VETERINARY PHARMACEUTICALS MARKET FOR COMPANION ANIMALS, BY TYPE, 2024–2031 (USD MILLION)
TABLE 128 CANADA: VETERINARY PHARMACEUTICALS MARKET FOR LIVESTOCK ANIMALS, BY TYPE, 2024–2031 (USD MILLION)
TABLE 129 CANADA: VETERINARY PHARMACEUTICALS MARKET, BY DISTRIBUTION CHANNEL, 2024–2031 (USD MILLION)
TABLE 130 CANADA: VETERINARY PHARMACEUTICALS MARKET, BY END USER, 2024–2031 (USD MILLION)
TABLE 131 EUROPE: VETERINARY PHARMACEUTICALS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 132 EUROPE: VETERINARY PHARMACEUTICALS MARKET, BY PRODUCT TYPE, 2024–2031 (USD MILLION)
TABLE 133 EUROPE: VETERINARY PHARMACEUTICALS MARKET, BY PRODUCT TYPE, 2024–2031 (THOUSAND UNITS)
TABLE 134 EUROPE: VETERINARY PHARMACEUTICALS MARKET FOR DRUGS, BY TYPE, 2024–2031 (USD MILLION)
TABLE 135 EUROPE: VETERINARY PHARMACEUTICALS MARKET FOR MEDICATED FEED ADDITIVES, BY TYPE, 2024–2031 (USD MILLION)
TABLE 136 EUROPE: VETERINARY PHARMACEUTICALS MARKET, BY ROUTE OF ADMINISTRATION, 2024–2031 (USD MILLION)
TABLE 137 EUROPE: VETERINARY PHARMACEUTICALS MARKET, BY FORMULATION TYPE, 2024–2031 (USD MILLION)
TABLE 138 EUROPE: VETERINARY PHARMACEUTICALS MARKET, BY INDICATION, 2024–2031 (USD MILLION)
TABLE 139 EUROPE: VETERINARY PHARMACEUTICALS MARKET, BY ANIMAL TYPE, 2024–2031 (USD MILLION)
TABLE 140 EUROPE: VETERINARY PHARMACEUTICALS MARKET FOR COMPANION ANIMALS, BY TYPE, 2024–2031 (USD MILLION)
TABLE 141 EUROPE: VETERINARY PHARMACEUTICALS MARKET FOR LIVESTOCK ANIMALS, BY TYPE, 2024–2031 (USD MILLION)
TABLE 142 EUROPE: VETERINARY PHARMACEUTICALS MARKET, BY DISTRIBUTION CHANNEL, 2024–2031 (USD MILLION)
TABLE 143 EUROPE: VETERINARY PHARMACEUTICALS MARKET, BY END USER, 2024–2031 (USD MILLION)
TABLE 144 GERMANY: KEY MACRO INDICATORS
TABLE 145 GERMANY: VETERINARY PHARMACEUTICALS MARKET, BY PRODUCT TYPE, 2024–2031 (USD MILLION)
TABLE 146 GERMANY: VETERINARY PHARMACEUTICALS MARKET FOR DRUGS, BY TYPE, 2024–2031 (USD MILLION)
TABLE 147 GERMANY: VETERINARY PHARMACEUTICALS MARKET FOR MEDICATED FEED ADDITIVES, BY TYPE, 2024–2031 (USD MILLION)
TABLE 148 GERMANY: VETERINARY PHARMACEUTICALS MARKET, BY ROUTE OF ADMINISTRATION, 2024–2031 (USD MILLION)
TABLE 149 GERMANY: VETERINARY PHARMACEUTICALS MARKET, BY FORMULATION TYPE, 2024–2031 (USD MILLION)
TABLE 150 GERMANY: VETERINARY PHARMACEUTICALS MARKET, BY INDICATION, 2024–2031 (USD MILLION)
TABLE 151 GERMANY: VETERINARY PHARMACEUTICALS MARKET, BY ANIMAL TYPE, 2024–2031 (USD MILLION)
TABLE 152 GERMANY: VETERINARY PHARMACEUTICALS MARKET FOR COMPANION ANIMALS, BY TYPE, 2024–2031 (USD MILLION)
TABLE 153 GERMANY: VETERINARY PHARMACEUTICALS MARKET FOR LIVESTOCK ANIMALS, BY TYPE, 2024–2031 (USD MILLION)
TABLE 154 GERMANY: VETERINARY PHARMACEUTICALS MARKET, BY DISTRIBUTION CHANNEL, 2024–2031 (USD MILLION)
TABLE 155 GERMANY: VETERINARY PHARMACEUTICALS MARKET, BY END USER, 2024–2031 (USD MILLION)
TABLE 156 UK: KEY MACRO INDICATORS
TABLE 157 UK: VETERINARY PHARMACEUTICALS MARKET, BY PRODUCT TYPE, 2024–2031 (USD MILLION)
TABLE 158 UK: VETERINARY PHARMACEUTICALS MARKET FOR DRUGS, BY TYPE, 2024–2031 (USD MILLION)
TABLE 159 UK: VETERINARY PHARMACEUTICALS MARKET FOR MEDICATED FEED ADDITIVES, BY TYPE, 2024–2031 (USD MILLION)
TABLE 160 UK: VETERINARY PHARMACEUTICALS MARKET, BY ROUTE OF ADMINISTRATION, 2024–2031 (USD MILLION)
TABLE 161 UK: VETERINARY PHARMACEUTICALS MARKET, BY FORMULATION TYPE, 2024–2031 (USD MILLION)
TABLE 162 UK: VETERINARY PHARMACEUTICALS MARKET, BY INDICATION, 2024–2031 (USD MILLION)
TABLE 163 UK: VETERINARY PHARMACEUTICALS MARKET, BY ANIMAL TYPE, 2024–2031 (USD MILLION)
TABLE 164 UK: VETERINARY PHARMACEUTICALS MARKET FOR COMPANION ANIMALS, BY TYPE, 2024–2031 (USD MILLION)
TABLE 165 UK: VETERINARY PHARMACEUTICALS MARKET FOR LIVESTOCK ANIMALS, BY TYPE, 2024–2031 (USD MILLION)
TABLE 166 UK: VETERINARY PHARMACEUTICALS MARKET, BY DISTRIBUTION CHANNEL, 2024–2031 (USD MILLION)
TABLE 167 UK: VETERINARY PHARMACEUTICALS MARKET, BY END USER, 2024–2031 (USD MILLION)
TABLE 168 FRANCE: KEY MACRO INDICATORS
TABLE 169 FRANCE: VETERINARY PHARMACEUTICALS MARKET, BY PRODUCT TYPE, 2024–2031 (USD MILLION)
TABLE 170 FRANCE: VETERINARY PHARMACEUTICALS MARKET FOR DRUGS, BY TYPE, 2024–2031 (USD MILLION)
TABLE 171 FRANCE: VETERINARY PHARMACEUTICALS MARKET FOR MEDICATED FEED ADDITIVES, BY TYPE, 2024–2031 (USD MILLION)
TABLE 172 FRANCE: VETERINARY PHARMACEUTICALS MARKET, BY ROUTE OF ADMINISTRATION, 2024–2031 (USD MILLION)
TABLE 173 FRANCE: VETERINARY PHARMACEUTICALS MARKET, BY FORMULATION TYPE, 2024–2031 (USD MILLION)
TABLE 174 FRANCE: VETERINARY PHARMACEUTICALS MARKET, BY INDICATION, 2024–2031 (USD MILLION)
TABLE 175 FRANCE: VETERINARY PHARMACEUTICALS MARKET, BY ANIMAL TYPE, 2024–2031 (USD MILLION)
TABLE 176 FRANCE: VETERINARY PHARMACEUTICALS MARKET FOR COMPANION ANIMALS, BY TYPE, 2024–2031 (USD MILLION)
TABLE 177 FRANCE: VETERINARY PHARMACEUTICALS MARKET FOR LIVESTOCK ANIMALS, BY TYPE, 2024–2031 (USD MILLION)
TABLE 178 FRANCE: VETERINARY PHARMACEUTICALS MARKET, BY DISTRIBUTION CHANNEL, 2024–2031 (USD MILLION)
TABLE 179 FRANCE: VETERINARY PHARMACEUTICALS MARKET, BY END USER, 2024–2031 (USD MILLION)
TABLE 180 ITALY: KEY MACRO INDICATORS
TABLE 181 ITALY: VETERINARY PHARMACEUTICALS MARKET, BY PRODUCT TYPE, 2024–2031 (USD MILLION)
TABLE 182 ITALY: VETERINARY PHARMACEUTICALS MARKET FOR DRUGS, BY TYPE, 2024–2031 (USD MILLION)
TABLE 183 ITALY: VETERINARY PHARMACEUTICALS MARKET FOR MEDICATED FEED ADDITIVES, BY TYPE, 2024–2031 (USD MILLION)
TABLE 184 ITALY: VETERINARY PHARMACEUTICALS MARKET, BY ROUTE OF ADMINISTRATION, 2024–2031 (USD MILLION)
TABLE 185 ITALY: VETERINARY PHARMACEUTICALS MARKET, BY FORMULATION TYPE, 2024–2031 (USD MILLION)
TABLE 186 ITALY: VETERINARY PHARMACEUTICALS MARKET, BY INDICATION, 2024–2031 (USD MILLION)
TABLE 187 ITALY: VETERINARY PHARMACEUTICALS MARKET, BY ANIMAL TYPE, 2024–2031 (USD MILLION)
TABLE 188 ITALY: VETERINARY PHARMACEUTICALS MARKET FOR COMPANION ANIMALS, BY TYPE, 2024–2031 (USD MILLION)
TABLE 189 ITALY: VETERINARY PHARMACEUTICALS MARKET FOR LIVESTOCK ANIMALS, BY TYPE, 2024–2031 (USD MILLION)
TABLE 190 ITALY: VETERINARY PHARMACEUTICALS MARKET, BY DISTRIBUTION CHANNEL, 2024–2031 (USD MILLION)
TABLE 191 ITALY: VETERINARY PHARMACEUTICALS MARKET, BY END USER, 2024–2031 (USD MILLION)
TABLE 192 SPAIN: KEY MACRO INDICATORS
TABLE 193 SPAIN: VETERINARY PHARMACEUTICALS MARKET, BY PRODUCT TYPE, 2024–2031 (USD MILLION)
TABLE 194 SPAIN: VETERINARY PHARMACEUTICALS MARKET FOR DRUGS, BY TYPE, 2024–2031 (USD MILLION)
TABLE 195 SPAIN: VETERINARY PHARMACEUTICALS MARKET FOR MEDICATED FEED ADDITIVES, BY TYPE, 2024–2031 (USD MILLION)
TABLE 196 SPAIN: VETERINARY PHARMACEUTICALS MARKET, BY ROUTE OF ADMINISTRATION, 2024–2031 (USD MILLION)
TABLE 197 SPAIN: VETERINARY PHARMACEUTICALS MARKET, BY FORMULATION TYPE, 2024–2031 (USD MILLION)
TABLE 198 SPAIN: VETERINARY PHARMACEUTICALS MARKET, BY INDICATION, 2024–2031 (USD MILLION)
TABLE 199 SPAIN: VETERINARY PHARMACEUTICALS MARKET, BY ANIMAL TYPE, 2024–2031 (USD MILLION)
TABLE 200 SPAIN: VETERINARY PHARMACEUTICALS MARKET FOR COMPANION ANIMALS, BY TYPE, 2024–2031 (USD MILLION)
TABLE 201 SPAIN: VETERINARY PHARMACEUTICALS MARKET FOR LIVESTOCK ANIMALS, BY TYPE, 2024–2031 (USD MILLION)
TABLE 202 SPAIN: VETERINARY PHARMACEUTICALS MARKET, BY DISTRIBUTION CHANNEL, 2024–2031 (USD MILLION)
TABLE 203 SPAIN: VETERINARY PHARMACEUTICALS MARKET, BY END USER, 2024–2031 (USD MILLION)
TABLE 204 REST OF EUROPE: VETERINARY PHARMACEUTICALS MARKET, BY PRODUCT TYPE, 2024–2031 (USD MILLION)
TABLE 205 REST OF EUROPE: VETERINARY PHARMACEUTICALS MARKET FOR DRUGS, BY TYPE, 2024–2031 (USD MILLION)
TABLE 206 REST OF EUROPE: VETERINARY PHARMACEUTICALS MARKET FOR MEDICATED FEED ADDITIVES, BY TYPE, 2024–2031 (USD MILLION)
TABLE 207 REST OF EUROPE: VETERINARY PHARMACEUTICALS MARKET, BY ROUTE OF ADMINISTRATION, 2024–2031 (USD MILLION)
TABLE 208 REST OF EUROPE: VETERINARY PHARMACEUTICALS MARKET, BY FORMULATION TYPE, 2024–2031 (USD MILLION)
TABLE 209 REST OF EUROPE: VETERINARY PHARMACEUTICALS MARKET, BY INDICATION, 2024–2031 (USD MILLION)
TABLE 210 REST OF EUROPE: VETERINARY PHARMACEUTICALS MARKET, BY ANIMAL TYPE, 2024–2031 (USD MILLION)
TABLE 211 REST OF EUROPE: VETERINARY PHARMACEUTICALS MARKET FOR COMPANION ANIMALS, BY TYPE, 2024–2031 (USD MILLION)
TABLE 212 REST OF EUROPE: VETERINARY PHARMACEUTICALS MARKET FOR LIVESTOCK ANIMALS, BY TYPE, 2024–2031 (USD MILLION)
TABLE 213 REST OF EUROPE: VETERINARY PHARMACEUTICALS MARKET, BY DISTRIBUTION CHANNEL, 2024–2031 (USD MILLION)
TABLE 214 REST OF EUROPE: VETERINARY PHARMACEUTICALS MARKET, BY END USER, 2024–2031 (USD MILLION)
TABLE 215 ASIA PACIFIC: VETERINARY PHARMACEUTICALS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 216 ASIA PACIFIC: VETERINARY PHARMACEUTICALS MARKET, BY PRODUCT TYPE, 2024–2031 (USD MILLION)
TABLE 217 ASIA PACIFIC: VETERINARY PHARMACEUTICALS MARKET, BY PRODUCT TYPE, 2024–2031 (THOUSAND UNITS)
TABLE 218 ASIA PACIFIC: VETERINARY PHARMACEUTICALS MARKET FOR DRUGS, BY TYPE, 2024–2031 (USD MILLION)
TABLE 219 ASIA PACIFIC: VETERINARY PHARMACEUTICALS MARKET FOR MEDICATED FEED ADDITIVES, BY TYPE, 2024–2031 (USD MILLION)
TABLE 220 ASIA PACIFIC: VETERINARY PHARMACEUTICALS MARKET, BY ROUTE OF ADMINISTRATION, 2024–2031 (USD MILLION)
TABLE 221 ASIA PACIFIC: VETERINARY PHARMACEUTICALS MARKET, BY FORMULATION TYPE, 2024–2031 (USD MILLION)
TABLE 222 ASIA PACIFIC: VETERINARY PHARMACEUTICALS MARKET, BY INDICATION, 2024–2031 (USD MILLION)
TABLE 223 ASIA PACIFIC: VETERINARY PHARMACEUTICALS MARKET, BY ANIMAL TYPE, 2024–2031 (USD MILLION)
TABLE 224 ASIA PACIFIC: VETERINARY PHARMACEUTICALS MARKET FOR COMPANION ANIMALS, BY TYPE, 2024–2031 (USD MILLION)
TABLE 225 ASIA PACIFIC: VETERINARY PHARMACEUTICALS MARKET FOR LIVESTOCK ANIMALS, BY TYPE, 2024–2031 (USD MILLION)
TABLE 226 ASIA PACIFIC: VETERINARY PHARMACEUTICALS MARKET, BY DISTRIBUTION CHANNEL, 2024–2031 (USD MILLION)
TABLE 227 ASIA PACIFIC: VETERINARY PHARMACEUTICALS MARKET, BY END USER, 2024–2031 (USD MILLION)
TABLE 228 JAPAN: KEY MACRO INDICATORS
TABLE 229 JAPAN: VETERINARY PHARMACEUTICALS MARKET, BY PRODUCT TYPE, 2024–2031 (USD MILLION)
TABLE 230 JAPAN: VETERINARY PHARMACEUTICALS MARKET FOR DRUGS, BY TYPE, 2024–2031 (USD MILLION)
TABLE 231 JAPAN: VETERINARY PHARMACEUTICALS MARKET FOR MEDICATED FEED ADDITIVES, BY TYPE, 2024–2031 (USD MILLION)
TABLE 232 JAPAN: VETERINARY PHARMACEUTICALS MARKET, BY ROUTE OF ADMINISTRATION, 2024–2031 (USD MILLION)
TABLE 233 JAPAN: VETERINARY PHARMACEUTICALS MARKET, BY FORMULATION TYPE, 2024–2031 (USD MILLION)
TABLE 234 JAPAN: VETERINARY PHARMACEUTICALS MARKET, BY INDICATION, 2024–2031 (USD MILLION)
TABLE 235 JAPAN: VETERINARY PHARMACEUTICALS MARKET, BY ANIMAL TYPE, 2024–2031 (USD MILLION)
TABLE 236 JAPAN: VETERINARY PHARMACEUTICALS MARKET FOR COMPANION ANIMALS, BY TYPE, 2024–2031 (USD MILLION)
TABLE 237 JAPAN: VETERINARY PHARMACEUTICALS MARKET FOR LIVESTOCK ANIMALS, BY TYPE, 2024–2031 (USD MILLION)
TABLE 238 JAPAN: VETERINARY PHARMACEUTICALS MARKET, BY DISTRIBUTION CHANNEL, 2024–2031 (USD MILLION)
TABLE 239 JAPAN: VETERINARY PHARMACEUTICALS MARKET, BY END USER, 2024–2031 (USD MILLION)
TABLE 1 STANDARD CURRENCY CONVERSION RATES (UNIT OF USD)
TABLE 2 PET (DOGS AND CATS) OWNERSHIP STATISTICS IN US, 2024
TABLE 3 COMPANION ANIMAL POPULATION STATISTICS, BY REGION
TABLE 4 RECENT GOVERNMENT-REPORTED INDICATORS
TABLE 5 TRENDS IN CONSUMPTION OF MEAT & MILK IN DEVELOPED & EMERGING ECONOMIES
TABLE 6 ASIA: COUNTRY-LEVEL CONSUMPTION OF ANIMAL-DERIVED FOOD PRODUCTS, 2020 VS. 2030 (THOUSAND METRIC TONS)
TABLE 7 ASIA: COUNTRY-LEVEL PRODUCTION OF ANIMAL-DERIVED FOOD PRODUCTS, 2020 VS. 2030 (THOUSAND METRIC TONS)
TABLE 8 UNMET CUSTOMER NEEDS AND WHITE SPACES IN VETERINARY PHARMACEUTICALS MARKET.
TABLE 9 INTERCONNECTED MARKETS IN VETERINARY PHARMACEUTICALS MARKET
TABLE 10 CROSS-SECTOR MARKETS IN VETERINARY PHARMACEUTICALS MARKET
TABLE 11 STRATEGIC MOVES BY TIER-1/2/3 PLAYERS
TABLE 12 IMPACT OF PORTER’S FIVE FORCES ON VETERINARY PHARMACEUTICALS MARKET
TABLE 13 GDP TREND AND FORECAST, BY COUNTRY, 2021–2030 (USD BILLION)
TABLE 14 AVERAGE SELLING PRICE TREND OF PRODUCTS, BY KEY PLAYERS, 2023–2025
TABLE 15 AVERAGE SELLING PRICE TREND OF FORMULATION TYPES, BY KEY PLAYERS, 2023–2025
TABLE 16 AVERAGE SELLING PRICE TREND OF PRODUCTS, BY REGION, 2023–2025
TABLE 17 IMPORT DATA FOR HS CODE 30, BY COUNTRY, 2021–2024 (USD MILLION)
TABLE 18 EXPORT DATA FOR HS CODE 30, BY COUNTRY, 2021–2024 (USD MILLION)
TABLE 19 DETAILED LIST OF CONFERENCES AND EVENTS, 2026–2027
TABLE 20 US ADJUSTED RECIPROCAL TARIFF RATES
TABLE 21 TECHNOLOGY/PRODUCT ROADMAP
TABLE 22 VETERINARY PHARMACEUTICALS MARKET: LIST OF MAJOR PATENTS, JANUARY 2023–DECEMBER 2025
TABLE 23 NORTH AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
TABLE 24 EUROPE: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
TABLE 25 ASIA PACIFIC: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
TABLE 26 REST OF THE WORLD: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
TABLE 27 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS FOR VETERINARY PHARMACEUTICAL PRODUCTS
TABLE 28 KEY BUYING CRITERIA FOR TOP THREE END USERS
TABLE 29 VETERINARY PHARMACEUTICALS MARKET: UNMET NEEDS IN KEY END-USE SETTINGS
TABLE 30 VETERINARY PHARMACEUTICALS MARKET, BY PRODUCT TYPE, 2024–2031 (THOUSAND UNITS)
TABLE 31 VETERINARY PHARMACEUTICALS MARKET, BY PRODUCT TYPE, 2024–2031 (USD MILLION)
TABLE 32 VETERINARY PHARMACEUTICALS MARKET FOR DRUGS, BY TYPE, 2024–2031 (USD MILLION)
TABLE 33 VETERINARY PHARMACEUTICALS MARKET FOR DRUGS, BY COUNTRY/REGION, 2024–2031 (USD MILLION)
TABLE 34 VETERINARY PHARMACEUTICALS MARKET FOR ANTI-BACTERIAL DRUGS, BY COUNTRY/REGION, 2024–2031 (USD MILLION)
TABLE 35 VETERINARY PHARMACEUTICALS MARKET FOR ANTI-FUNGAL DRUGS, BY COUNTRY/REGION, 2024–2031 (USD MILLION)
TABLE 36 VETERINARY PHARMACEUTICALS MARKET FOR ANTI-VIRAL DRUGS, BY COUNTRY/REGION, 2024–2031 (USD MILLION)
TABLE 37 VETERINARY PHARMACEUTICALS MARKET FOR ANTI-INFLAMMATORY DRUGS, BY COUNTRY/REGION, 2024–2031 (USD MILLION)
TABLE 38 VETERINARY PHARMACEUTICALS MARKET FOR ANTI-PARASITIC DRUGS, BY COUNTRY/REGION, 2024–2031 (USD MILLION)
TABLE 39 VETERINARY PHARMACEUTICALS MARKET FOR ANTI-CANCER DRUGS, BY COUNTRY/REGION, 2024–2031 (USD MILLION)
TABLE 40 VETERINARY PHARMACEUTICALS MARKET FOR CARDIOVASCULAR AND RENAL DRUGS, BY COUNTRY/REGION, 2024–2031 (USD MILLION)
TABLE 41 VETERINARY PHARMACEUTICALS MARKET FOR GASTROINTESTINAL DRUGS, BY COUNTRY/REGION, 2024–2031 (USD MILLION)
TABLE 42 VETERINARY PHARMACEUTICALS MARKET FOR OTHER DRUGS, BY COUNTRY/REGION, 2024–2031 (USD MILLION)
TABLE 43 VETERINARY PHARMACEUTICALS MARKET FOR MONOCLONAL ANTIBODIES, BY COUNTRY/REGION, 2024–2031 (USD MILLION)
TABLE 44 VETERINARY PHARMACEUTICALS MARKET FOR IMMUNOMODULATORS, BY COUNTRY/REGION, 2024–2031 (USD MILLION)
TABLE 45 VETERINARY PHARMACEUTICALS MARKET FOR MEDICATED FEED ADDITIVES, BY TYPE, 2024–2031 (USD MILLION)
TABLE 46 VETERINARY PHARMACEUTICALS MARKET FOR MEDICATED FEED ADDITIVES, BY COUNTRY/REGION, 2024–2031 (USD MILLION)
TABLE 47 VETERINARY PHARMACEUTICALS MARKET FOR AMINO ACIDS, BY COUNTRY/REGION, 2024–2031 (USD MILLION)
TABLE 48 VETERINARY PHARMACEUTICALS MARKET FOR ENZYMES, BY COUNTRY/REGION, 2024–2031 (USD MILLION)
TABLE 49 VETERINARY PHARMACEUTICALS MARKET FOR VITAMINS AND MINERALS, BY COUNTRY/REGION, 2024–2031 (USD MILLION)
TABLE 50 VETERINARY PHARMACEUTICALS MARKET FOR OTHER MEDICATED FEED ADDITIVES, BY COUNTRY/REGION, 2024–2031 (USD MILLION)
TABLE 51 VETERINARY PHARMACEUTICALS MARKET, BY ROUTE OF ADMINISTRATION, 2024–2031 (USD MILLION)
TABLE 52 VETERINARY PHARMACEUTICALS MARKET FOR ORAL, BY COUNTRY/REGION, 2024–2031 (USD MILLION)
TABLE 53 VETERINARY PHARMACEUTICALS MARKET FOR PARENTERAL, BY COUNTRY/REGION, 2024–2031 (USD MILLION)
TABLE 54 VETERINARY PHARMACEUTICALS MARKET FOR TOPICAL, BY COUNTRY/REGION, 2024–2031 (USD MILLION)
TABLE 55 VETERINARY PHARMACEUTICALS MARKET FOR OTHER ROUTES OF ADMINISTRATION, BY COUNTRY/REGION, 2024–2031 (USD MILLION)
TABLE 56 VETERINARY PHARMACEUTICALS MARKET, BY FORMULATION TYPE, 2024–2031 (USD MILLION)
TABLE 57 VETERINARY PHARMACEUTICALS MARKET FOR SOLID, BY COUNTRY/REGION, 2024–2031 (USD MILLION)
TABLE 58 VETERINARY PHARMACEUTICALS MARKET FOR LIQUID, BY COUNTRY/REGION, 2024–2031 (USD MILLION)
TABLE 59 VETERINARY PHARMACEUTICALS MARKET FOR SEMI-SOLID, BY COUNTRY/REGION, 2024–2031 (USD MILLION)
TABLE 60 VETERINARY PHARMACEUTICALS MARKET FOR AEROSOL/SPRAY, BY COUNTRY/REGION, 2024–2031 (USD MILLION)
TABLE 61 VETERINARY PHARMACEUTICALS MARKET FOR PREMIX FORMULATIONS, BY COUNTRY/REGION, 2024–2031 (USD MILLION)
TABLE 62 VETERINARY PHARMACEUTICALS MARKET, BY INDICATION, 2024–2031 (USD MILLION)
TABLE 63 VETERINARY PHARMACEUTICALS MARKET FOR INFECTIOUS DISEASES, BY COUNTRY/REGION, 2024–2031 (USD MILLION)
TABLE 64 VETERINARY PHARMACEUTICALS MARKET FOR DERMATOLOGICAL DISEASES, BY COUNTRY/REGION, 2024–2031 (USD MILLION)
TABLE 65 VETERINARY PHARMACEUTICALS MARKET FOR PAIN MANAGEMENT, BY COUNTRY/REGION, 2024–2031 (USD MILLION)
TABLE 66 VETERINARY PHARMACEUTICALS MARKET FOR CARDIOVASCULAR AND RENAL DISEASES, BY COUNTRY/REGION, 2024–2031 (USD MILLION)
TABLE 67 VETERINARY PHARMACEUTICALS MARKET FOR GASTROINTESTINAL DISEASES, BY COUNTRY/REGION, 2024–2031 (USD MILLION)
TABLE 68 VETERINARY PHARMACEUTICALS MARKET FOR OTHER INDICATIONS, BY COUNTRY/REGION, 2024–2031 (USD MILLION)
TABLE 69 VETERINARY PHARMACEUTICALS MARKET, BY ANIMAL TYPE, 2024–2031 (USD MILLION)
TABLE 70 VETERINARY PHARMACEUTICALS MARKET FOR COMPANION ANIMALS, BY TYPE, 2024–2031 (USD MILLION)
TABLE 71 VETERINARY PHARMACEUTICALS MARKET FOR COMPANION ANIMALS, BY COUNTRY/REGION, 2024–2031 (USD MILLION)
TABLE 72 VETERINARY PHARMACEUTICALS MARKET FOR DOGS, BY COUNTRY/REGION, 2024–2031 (USD MILLION)
TABLE 73 VETERINARY PHARMACEUTICALS MARKET FOR CATS, BY COUNTRY/REGION, 2024–2031 (USD MILLION)
TABLE 74 VETERINARY PHARMACEUTICALS MARKET FOR HORSES, BY COUNTRY/REGION, 2024–2031 (USD MILLION)
TABLE 75 VETERINARY PHARMACEUTICALS MARKET FOR OTHER COMPANION ANIMALS, BY COUNTRY/REGION, 2024–2031 (USD MILLION)
TABLE 76 VETERINARY PHARMACEUTICALS MARKET FOR LIVESTOCK ANIMALS, BY TYPE, 2024–2031 (USD MILLION)
TABLE 77 VETERINARY PHARMACEUTICALS MARKET FOR LIVESTOCK ANIMALS, BY COUNTRY/REGION, 2024–2031 (USD MILLION)
TABLE 78 VETERINARY PHARMACEUTICALS MARKET FOR CATTLE, BY COUNTRY/ REGION, 2024–2031 (USD MILLION)
TABLE 79 VETERINARY PHARMACEUTICALS MARKET FOR SWINE, BY COUNTRY/REGION, 2024–2031 (USD MILLION)
TABLE 80 VETERINARY PHARMACEUTICALS MARKET FOR POULTRY, BY COUNTRY/REGION, 2024–2031 (USD MILLION)
TABLE 81 VETERINARY PHARMACEUTICALS MARKET FOR OTHER LIVESTOCK ANIMALS, BY COUNTRY/REGION, 2024–2031 (USD MILLION)
TABLE 82 VETERINARY PHARMACEUTICALS MARKET, BY DISTRIBUTION CHANNEL, 2024–2031 (USD MILLION)
TABLE 83 VETERINARY PHARMACEUTICALS MARKET FOR VETERINARY HOSPITAL PHARMACIES, BY COUNTRY/REGION, 2024–2031 (USD MILLION)
TABLE 84 VETERINARY PHARMACEUTICALS MARKET FOR RETAIL PHARMACIES, BY COUNTRY/REGION, 2024–2031 (USD MILLION)
TABLE 85 VETERINARY PHARMACEUTICALS MARKET FOR ONLINE PHARMACIES, BY COUNTRY/REGION, 2024–2031 (USD MILLION)
TABLE 86 VETERINARY PHARMACEUTICALS MARKET FOR DIRECT SALES, BY COUNTRY/REGION, 2024–2031 (USD MILLION)
TABLE 87 VETERINARY PHARMACEUTICALS MARKET, BY END USER, 2024–2031 (USD MILLION)
TABLE 88 VETERINARY PHARMACEUTICALS MARKET FOR VETERINARY HOSPITALS & CLINICS, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 89 VETERINARY PHARMACEUTICALS MARKET FOR LIVESTOCK FARMS, BY COUNTRY/REGION, 2024–2031 (USD MILLION)
TABLE 90 VETERINARY PHARMACEUTICALS MARKET FOR HOME CARE SETTINGS, BY COUNTRY/REGION, 2024–2031 (USD MILLION)
TABLE 91 VETERINARY PHARMACEUTICALS MARKET FOR OTHER END USERS, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 92 VETERINARY PHARMACEUTICALS MARKET, BY REGION, 2024–2031 (USD MILLION)
TABLE 93 VETERINARY PHARMACEUTICALS MARKET, BY COUNTRY/REGION, 2024–2031 (USD MILLION)
TABLE 94 NORTH AMERICA: VETERINARY PHARMACEUTICALS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 95 NORTH AMERICA: VETERINARY PHARMACEUTICALS MARKET, BY PRODUCT TYPE, 2024–2031 (USD MILLION)
TABLE 96 NORTH AMERICA: VETERINARY PHARMACEUTICALS MARKET, BY PRODUCT TYPE, 2024–2031 (THOUSAND UNITS)
TABLE 97 NORTH AMERICA: VETERINARY PHARMACEUTICALS MARKET FOR DRUGS, BY TYPE, 2024–2031 (USD MILLION)
TABLE 98 NORTH AMERICA: VETERINARY PHARMACEUTICALS MARKET FOR MEDICATED FEED ADDITIVES, BY TYPE, 2024–2031 (USD MILLION)
TABLE 99 NORTH AMERICA: VETERINARY PHARMACEUTICALS MARKET, BY ROUTE OF ADMINISTRATION, 2024–2031 (USD MILLION)
TABLE 100 NORTH AMERICA: VETERINARY PHARMACEUTICALS MARKET, BY FORMULATION TYPE, 2024–2031 (USD MILLION)
TABLE 101 NORTH AMERICA: VETERINARY PHARMACEUTICALS MARKET, BY INDICATION, 2024–2031 (USD MILLION)
TABLE 102 NORTH AMERICA: VETERINARY PHARMACEUTICALS MARKET, BY ANIMAL TYPE, 2024–2031 (USD MILLION)
TABLE 103 NORTH AMERICA: VETERINARY PHARMACEUTICALS MARKET FOR COMPANION ANIMALS, BY TYPE, 2024–2031 (USD MILLION)
TABLE 104 NORTH AMERICA: VETERINARY PHARMACEUTICALS MARKET FOR LIVESTOCK ANIMALS, BY TYPE, 2024–2031 (USD MILLION)
TABLE 105 NORTH AMERICA: VETERINARY PHARMACEUTICALS MARKET, BY DISTRIBUTION CHANNEL, 2024–2031 (USD MILLION)
TABLE 106 NORTH AMERICA: VETERINARY PHARMACEUTICALS MARKET, BY END USER, 2024–2031 (USD MILLION)
TABLE 107 US: KEY MACRO INDICATORS
TABLE 108 US: VETERINARY PHARMACEUTICALS MARKET, BY PRODUCT TYPE, 2024–2031 (USD MILLION)
TABLE 109 US: VETERINARY PHARMACEUTICALS MARKET FOR DRUGS, BY TYPE, 2024–2031 (USD MILLION)
TABLE 110 US: VETERINARY PHARMACEUTICALS MARKET FOR MEDICATED FEED ADDITIVES, BY TYPE, 2024–2031 (USD MILLION)
TABLE 111 US: VETERINARY PHARMACEUTICALS MARKET, BY ROUTE OF ADMINISTRATION, 2024–2031 (USD MILLION)
TABLE 112 US: VETERINARY PHARMACEUTICALS MARKET, BY FORMULATION TYPE, 2024–2031 (USD MILLION)
TABLE 113 US: VETERINARY PHARMACEUTICALS MARKET, BY INDICATION, 2024–2031 (USD MILLION)
TABLE 114 US: VETERINARY PHARMACEUTICALS MARKET, BY ANIMAL TYPE, 2024–2031 (USD MILLION)
TABLE 115 US: VETERINARY PHARMACEUTICALS MARKET FOR COMPANION ANIMALS, BY TYPE, 2024–2031 (USD MILLION)
TABLE 116 US: VETERINARY PHARMACEUTICALS MARKET FOR LIVESTOCK ANIMALS, BY TYPE, 2024–2031 (USD MILLION)
TABLE 117 US: VETERINARY PHARMACEUTICALS MARKET, BY DISTRIBUTION CHANNEL, 2024–2031 (USD MILLION)
TABLE 118 US: VETERINARY PHARMACEUTICALS MARKET, BY END USER, 2024–2031 (USD MILLION)
TABLE 119 CANADA: KEY MACRO INDICATORS
TABLE 120 CANADA: VETERINARY PHARMACEUTICALS MARKET, BY PRODUCT TYPE, 2024–2031 (USD MILLION)
TABLE 121 CANADA: VETERINARY PHARMACEUTICALS MARKET FOR DRUGS, BY TYPE, 2024–2031 (USD MILLION)
TABLE 122 CANADA: VETERINARY PHARMACEUTICALS MARKET FOR MEDICATED FEED ADDITIVES, BY TYPE, 2024–2031 (USD MILLION)
TABLE 123 CANADA: VETERINARY PHARMACEUTICALS MARKET, BY ROUTE OF ADMINISTRATION, 2024–2031 (USD MILLION)
TABLE 124 CANADA: VETERINARY PHARMACEUTICALS MARKET, BY FORMULATION TYPE, 2024–2031 (USD MILLION)
TABLE 125 CANADA: VETERINARY PHARMACEUTICALS MARKET, BY INDICATION, 2024–2031 (USD MILLION)
TABLE 126 CANADA: VETERINARY PHARMACEUTICALS MARKET, BY ANIMAL TYPE, 2024–2031 (USD MILLION)
TABLE 127 CANADA: VETERINARY PHARMACEUTICALS MARKET FOR COMPANION ANIMALS, BY TYPE, 2024–2031 (USD MILLION)
TABLE 128 CANADA: VETERINARY PHARMACEUTICALS MARKET FOR LIVESTOCK ANIMALS, BY TYPE, 2024–2031 (USD MILLION)
TABLE 129 CANADA: VETERINARY PHARMACEUTICALS MARKET, BY DISTRIBUTION CHANNEL, 2024–2031 (USD MILLION)
TABLE 130 CANADA: VETERINARY PHARMACEUTICALS MARKET, BY END USER, 2024–2031 (USD MILLION)
TABLE 131 EUROPE: VETERINARY PHARMACEUTICALS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 132 EUROPE: VETERINARY PHARMACEUTICALS MARKET, BY PRODUCT TYPE, 2024–2031 (USD MILLION)
TABLE 133 EUROPE: VETERINARY PHARMACEUTICALS MARKET, BY PRODUCT TYPE, 2024–2031 (THOUSAND UNITS)
TABLE 134 EUROPE: VETERINARY PHARMACEUTICALS MARKET FOR DRUGS, BY TYPE, 2024–2031 (USD MILLION)
TABLE 135 EUROPE: VETERINARY PHARMACEUTICALS MARKET FOR MEDICATED FEED ADDITIVES, BY TYPE, 2024–2031 (USD MILLION)
TABLE 136 EUROPE: VETERINARY PHARMACEUTICALS MARKET, BY ROUTE OF ADMINISTRATION, 2024–2031 (USD MILLION)
TABLE 137 EUROPE: VETERINARY PHARMACEUTICALS MARKET, BY FORMULATION TYPE, 2024–2031 (USD MILLION)
TABLE 138 EUROPE: VETERINARY PHARMACEUTICALS MARKET, BY INDICATION, 2024–2031 (USD MILLION)
TABLE 139 EUROPE: VETERINARY PHARMACEUTICALS MARKET, BY ANIMAL TYPE, 2024–2031 (USD MILLION)
TABLE 140 EUROPE: VETERINARY PHARMACEUTICALS MARKET FOR COMPANION ANIMALS, BY TYPE, 2024–2031 (USD MILLION)
TABLE 141 EUROPE: VETERINARY PHARMACEUTICALS MARKET FOR LIVESTOCK ANIMALS, BY TYPE, 2024–2031 (USD MILLION)
TABLE 142 EUROPE: VETERINARY PHARMACEUTICALS MARKET, BY DISTRIBUTION CHANNEL, 2024–2031 (USD MILLION)
TABLE 143 EUROPE: VETERINARY PHARMACEUTICALS MARKET, BY END USER, 2024–2031 (USD MILLION)
TABLE 144 GERMANY: KEY MACRO INDICATORS
TABLE 145 GERMANY: VETERINARY PHARMACEUTICALS MARKET, BY PRODUCT TYPE, 2024–2031 (USD MILLION)
TABLE 146 GERMANY: VETERINARY PHARMACEUTICALS MARKET FOR DRUGS, BY TYPE, 2024–2031 (USD MILLION)
TABLE 147 GERMANY: VETERINARY PHARMACEUTICALS MARKET FOR MEDICATED FEED ADDITIVES, BY TYPE, 2024–2031 (USD MILLION)
TABLE 148 GERMANY: VETERINARY PHARMACEUTICALS MARKET, BY ROUTE OF ADMINISTRATION, 2024–2031 (USD MILLION)
TABLE 149 GERMANY: VETERINARY PHARMACEUTICALS MARKET, BY FORMULATION TYPE, 2024–2031 (USD MILLION)
TABLE 150 GERMANY: VETERINARY PHARMACEUTICALS MARKET, BY INDICATION, 2024–2031 (USD MILLION)
TABLE 151 GERMANY: VETERINARY PHARMACEUTICALS MARKET, BY ANIMAL TYPE, 2024–2031 (USD MILLION)
TABLE 152 GERMANY: VETERINARY PHARMACEUTICALS MARKET FOR COMPANION ANIMALS, BY TYPE, 2024–2031 (USD MILLION)
TABLE 153 GERMANY: VETERINARY PHARMACEUTICALS MARKET FOR LIVESTOCK ANIMALS, BY TYPE, 2024–2031 (USD MILLION)
TABLE 154 GERMANY: VETERINARY PHARMACEUTICALS MARKET, BY DISTRIBUTION CHANNEL, 2024–2031 (USD MILLION)
TABLE 155 GERMANY: VETERINARY PHARMACEUTICALS MARKET, BY END USER, 2024–2031 (USD MILLION)
TABLE 156 UK: KEY MACRO INDICATORS
TABLE 157 UK: VETERINARY PHARMACEUTICALS MARKET, BY PRODUCT TYPE, 2024–2031 (USD MILLION)
TABLE 158 UK: VETERINARY PHARMACEUTICALS MARKET FOR DRUGS, BY TYPE, 2024–2031 (USD MILLION)
TABLE 159 UK: VETERINARY PHARMACEUTICALS MARKET FOR MEDICATED FEED ADDITIVES, BY TYPE, 2024–2031 (USD MILLION)
TABLE 160 UK: VETERINARY PHARMACEUTICALS MARKET, BY ROUTE OF ADMINISTRATION, 2024–2031 (USD MILLION)
TABLE 161 UK: VETERINARY PHARMACEUTICALS MARKET, BY FORMULATION TYPE, 2024–2031 (USD MILLION)
TABLE 162 UK: VETERINARY PHARMACEUTICALS MARKET, BY INDICATION, 2024–2031 (USD MILLION)
TABLE 163 UK: VETERINARY PHARMACEUTICALS MARKET, BY ANIMAL TYPE, 2024–2031 (USD MILLION)
TABLE 164 UK: VETERINARY PHARMACEUTICALS MARKET FOR COMPANION ANIMALS, BY TYPE, 2024–2031 (USD MILLION)
TABLE 165 UK: VETERINARY PHARMACEUTICALS MARKET FOR LIVESTOCK ANIMALS, BY TYPE, 2024–2031 (USD MILLION)
TABLE 166 UK: VETERINARY PHARMACEUTICALS MARKET, BY DISTRIBUTION CHANNEL, 2024–2031 (USD MILLION)
TABLE 167 UK: VETERINARY PHARMACEUTICALS MARKET, BY END USER, 2024–2031 (USD MILLION)
TABLE 168 FRANCE: KEY MACRO INDICATORS
TABLE 169 FRANCE: VETERINARY PHARMACEUTICALS MARKET, BY PRODUCT TYPE, 2024–2031 (USD MILLION)
TABLE 170 FRANCE: VETERINARY PHARMACEUTICALS MARKET FOR DRUGS, BY TYPE, 2024–2031 (USD MILLION)
TABLE 171 FRANCE: VETERINARY PHARMACEUTICALS MARKET FOR MEDICATED FEED ADDITIVES, BY TYPE, 2024–2031 (USD MILLION)
TABLE 172 FRANCE: VETERINARY PHARMACEUTICALS MARKET, BY ROUTE OF ADMINISTRATION, 2024–2031 (USD MILLION)
TABLE 173 FRANCE: VETERINARY PHARMACEUTICALS MARKET, BY FORMULATION TYPE, 2024–2031 (USD MILLION)
TABLE 174 FRANCE: VETERINARY PHARMACEUTICALS MARKET, BY INDICATION, 2024–2031 (USD MILLION)
TABLE 175 FRANCE: VETERINARY PHARMACEUTICALS MARKET, BY ANIMAL TYPE, 2024–2031 (USD MILLION)
TABLE 176 FRANCE: VETERINARY PHARMACEUTICALS MARKET FOR COMPANION ANIMALS, BY TYPE, 2024–2031 (USD MILLION)
TABLE 177 FRANCE: VETERINARY PHARMACEUTICALS MARKET FOR LIVESTOCK ANIMALS, BY TYPE, 2024–2031 (USD MILLION)
TABLE 178 FRANCE: VETERINARY PHARMACEUTICALS MARKET, BY DISTRIBUTION CHANNEL, 2024–2031 (USD MILLION)
TABLE 179 FRANCE: VETERINARY PHARMACEUTICALS MARKET, BY END USER, 2024–2031 (USD MILLION)
TABLE 180 ITALY: KEY MACRO INDICATORS
TABLE 181 ITALY: VETERINARY PHARMACEUTICALS MARKET, BY PRODUCT TYPE, 2024–2031 (USD MILLION)
TABLE 182 ITALY: VETERINARY PHARMACEUTICALS MARKET FOR DRUGS, BY TYPE, 2024–2031 (USD MILLION)
TABLE 183 ITALY: VETERINARY PHARMACEUTICALS MARKET FOR MEDICATED FEED ADDITIVES, BY TYPE, 2024–2031 (USD MILLION)
TABLE 184 ITALY: VETERINARY PHARMACEUTICALS MARKET, BY ROUTE OF ADMINISTRATION, 2024–2031 (USD MILLION)
TABLE 185 ITALY: VETERINARY PHARMACEUTICALS MARKET, BY FORMULATION TYPE, 2024–2031 (USD MILLION)
TABLE 186 ITALY: VETERINARY PHARMACEUTICALS MARKET, BY INDICATION, 2024–2031 (USD MILLION)
TABLE 187 ITALY: VETERINARY PHARMACEUTICALS MARKET, BY ANIMAL TYPE, 2024–2031 (USD MILLION)
TABLE 188 ITALY: VETERINARY PHARMACEUTICALS MARKET FOR COMPANION ANIMALS, BY TYPE, 2024–2031 (USD MILLION)
TABLE 189 ITALY: VETERINARY PHARMACEUTICALS MARKET FOR LIVESTOCK ANIMALS, BY TYPE, 2024–2031 (USD MILLION)
TABLE 190 ITALY: VETERINARY PHARMACEUTICALS MARKET, BY DISTRIBUTION CHANNEL, 2024–2031 (USD MILLION)
TABLE 191 ITALY: VETERINARY PHARMACEUTICALS MARKET, BY END USER, 2024–2031 (USD MILLION)
TABLE 192 SPAIN: KEY MACRO INDICATORS
TABLE 193 SPAIN: VETERINARY PHARMACEUTICALS MARKET, BY PRODUCT TYPE, 2024–2031 (USD MILLION)
TABLE 194 SPAIN: VETERINARY PHARMACEUTICALS MARKET FOR DRUGS, BY TYPE, 2024–2031 (USD MILLION)
TABLE 195 SPAIN: VETERINARY PHARMACEUTICALS MARKET FOR MEDICATED FEED ADDITIVES, BY TYPE, 2024–2031 (USD MILLION)
TABLE 196 SPAIN: VETERINARY PHARMACEUTICALS MARKET, BY ROUTE OF ADMINISTRATION, 2024–2031 (USD MILLION)
TABLE 197 SPAIN: VETERINARY PHARMACEUTICALS MARKET, BY FORMULATION TYPE, 2024–2031 (USD MILLION)
TABLE 198 SPAIN: VETERINARY PHARMACEUTICALS MARKET, BY INDICATION, 2024–2031 (USD MILLION)
TABLE 199 SPAIN: VETERINARY PHARMACEUTICALS MARKET, BY ANIMAL TYPE, 2024–2031 (USD MILLION)
TABLE 200 SPAIN: VETERINARY PHARMACEUTICALS MARKET FOR COMPANION ANIMALS, BY TYPE, 2024–2031 (USD MILLION)
TABLE 201 SPAIN: VETERINARY PHARMACEUTICALS MARKET FOR LIVESTOCK ANIMALS, BY TYPE, 2024–2031 (USD MILLION)
TABLE 202 SPAIN: VETERINARY PHARMACEUTICALS MARKET, BY DISTRIBUTION CHANNEL, 2024–2031 (USD MILLION)
TABLE 203 SPAIN: VETERINARY PHARMACEUTICALS MARKET, BY END USER, 2024–2031 (USD MILLION)
TABLE 204 REST OF EUROPE: VETERINARY PHARMACEUTICALS MARKET, BY PRODUCT TYPE, 2024–2031 (USD MILLION)
TABLE 205 REST OF EUROPE: VETERINARY PHARMACEUTICALS MARKET FOR DRUGS, BY TYPE, 2024–2031 (USD MILLION)
TABLE 206 REST OF EUROPE: VETERINARY PHARMACEUTICALS MARKET FOR MEDICATED FEED ADDITIVES, BY TYPE, 2024–2031 (USD MILLION)
TABLE 207 REST OF EUROPE: VETERINARY PHARMACEUTICALS MARKET, BY ROUTE OF ADMINISTRATION, 2024–2031 (USD MILLION)
TABLE 208 REST OF EUROPE: VETERINARY PHARMACEUTICALS MARKET, BY FORMULATION TYPE, 2024–2031 (USD MILLION)
TABLE 209 REST OF EUROPE: VETERINARY PHARMACEUTICALS MARKET, BY INDICATION, 2024–2031 (USD MILLION)
TABLE 210 REST OF EUROPE: VETERINARY PHARMACEUTICALS MARKET, BY ANIMAL TYPE, 2024–2031 (USD MILLION)
TABLE 211 REST OF EUROPE: VETERINARY PHARMACEUTICALS MARKET FOR COMPANION ANIMALS, BY TYPE, 2024–2031 (USD MILLION)
TABLE 212 REST OF EUROPE: VETERINARY PHARMACEUTICALS MARKET FOR LIVESTOCK ANIMALS, BY TYPE, 2024–2031 (USD MILLION)
TABLE 213 REST OF EUROPE: VETERINARY PHARMACEUTICALS MARKET, BY DISTRIBUTION CHANNEL, 2024–2031 (USD MILLION)
TABLE 214 REST OF EUROPE: VETERINARY PHARMACEUTICALS MARKET, BY END USER, 2024–2031 (USD MILLION)
TABLE 215 ASIA PACIFIC: VETERINARY PHARMACEUTICALS MARKET, BY COUNTRY, 2024–2031 (USD MILLION)
TABLE 216 ASIA PACIFIC: VETERINARY PHARMACEUTICALS MARKET, BY PRODUCT TYPE, 2024–2031 (USD MILLION)
TABLE 217 ASIA PACIFIC: VETERINARY PHARMACEUTICALS MARKET, BY PRODUCT TYPE, 2024–2031 (THOUSAND UNITS)
TABLE 218 ASIA PACIFIC: VETERINARY PHARMACEUTICALS MARKET FOR DRUGS, BY TYPE, 2024–2031 (USD MILLION)
TABLE 219 ASIA PACIFIC: VETERINARY PHARMACEUTICALS MARKET FOR MEDICATED FEED ADDITIVES, BY TYPE, 2024–2031 (USD MILLION)
TABLE 220 ASIA PACIFIC: VETERINARY PHARMACEUTICALS MARKET, BY ROUTE OF ADMINISTRATION, 2024–2031 (USD MILLION)
TABLE 221 ASIA PACIFIC: VETERINARY PHARMACEUTICALS MARKET, BY FORMULATION TYPE, 2024–2031 (USD MILLION)
TABLE 222 ASIA PACIFIC: VETERINARY PHARMACEUTICALS MARKET, BY INDICATION, 2024–2031 (USD MILLION)
TABLE 223 ASIA PACIFIC: VETERINARY PHARMACEUTICALS MARKET, BY ANIMAL TYPE, 2024–2031 (USD MILLION)
TABLE 224 ASIA PACIFIC: VETERINARY PHARMACEUTICALS MARKET FOR COMPANION ANIMALS, BY TYPE, 2024–2031 (USD MILLION)
TABLE 225 ASIA PACIFIC: VETERINARY PHARMACEUTICALS MARKET FOR LIVESTOCK ANIMALS, BY TYPE, 2024–2031 (USD MILLION)
TABLE 226 ASIA PACIFIC: VETERINARY PHARMACEUTICALS MARKET, BY DISTRIBUTION CHANNEL, 2024–2031 (USD MILLION)
TABLE 227 ASIA PACIFIC: VETERINARY PHARMACEUTICALS MARKET, BY END USER, 2024–2031 (USD MILLION)
TABLE 228 JAPAN: KEY MACRO INDICATORS
TABLE 229 JAPAN: VETERINARY PHARMACEUTICALS MARKET, BY PRODUCT TYPE, 2024–2031 (USD MILLION)
TABLE 230 JAPAN: VETERINARY PHARMACEUTICALS MARKET FOR DRUGS, BY TYPE, 2024–2031 (USD MILLION)
TABLE 231 JAPAN: VETERINARY PHARMACEUTICALS MARKET FOR MEDICATED FEED ADDITIVES, BY TYPE, 2024–2031 (USD MILLION)
TABLE 232 JAPAN: VETERINARY PHARMACEUTICALS MARKET, BY ROUTE OF ADMINISTRATION, 2024–2031 (USD MILLION)
TABLE 233 JAPAN: VETERINARY PHARMACEUTICALS MARKET, BY FORMULATION TYPE, 2024–2031 (USD MILLION)
TABLE 234 JAPAN: VETERINARY PHARMACEUTICALS MARKET, BY INDICATION, 2024–2031 (USD MILLION)
TABLE 235 JAPAN: VETERINARY PHARMACEUTICALS MARKET, BY ANIMAL TYPE, 2024–2031 (USD MILLION)
TABLE 236 JAPAN: VETERINARY PHARMACEUTICALS MARKET FOR COMPANION ANIMALS, BY TYPE, 2024–2031 (USD MILLION)
TABLE 237 JAPAN: VETERINARY PHARMACEUTICALS MARKET FOR LIVESTOCK ANIMALS, BY TYPE, 2024–2031 (USD MILLION)
TABLE 238 JAPAN: VETERINARY PHARMACEUTICALS MARKET, BY DISTRIBUTION CHANNEL, 2024–2031 (USD MILLION)
TABLE 239 JAPAN: VETERINARY PHARMACEUTICALS MARKET, BY END USER, 2024–2031 (USD MILLION)
LIST OF FIGURES
FIGURE 1 VETERINARY PHARMACEUTICALS MARKET SEGMENTATION
FIGURE 2 MARKET SCENARIO
FIGURE 3 VETERINARY PHARMACEUTICALS MARKET, 2024–2031
FIGURE 4 VETERINARY PHARMACEUTICALS MARKET: MAJOR STRATEGIES ADOPTED BY KEY PLAYERS, 2022–2025
FIGURE 5 DISRUPTIONS INFLUENCING GROWTH OF VETERINARY PHARMACEUTICALS MARKET
FIGURE 6 VETERINARY PHARMACEUTICALS MARKET: HIGH-GROWTH SEGMENTS, 2026–2031
FIGURE 7 ASIA PACIFIC TO REGISTER HIGHEST CAGR DURING FORECAST PERIOD
FIGURE 8 INCREASING PET CARE EXPENDITURE TO DRIVE MARKET
FIGURE 9 DRUGS SEGMENT AND CHINA DOMINATED MARKET IN 2025
FIGURE 10 ASIA PACIFIC TO REGISTER HIGHEST GROWTH RATE DURING FORECAST PERIOD
FIGURE 11 DEVELOPING ECONOMIES TO REGISTER HIGHER GROWTH RATES DURING FORECAST PERIOD
FIGURE 12 VETERINARY PHARMACEUTICALS MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES
FIGURE 13 PET POPULATION IN MAJOR MARKETS, 2022 (MILLION)
FIGURE 14 EUROPE: PET POPULATION, 2021–2023
FIGURE 15 VETERINARY PHARMACEUTICALS MARKET: PORTER’S FIVE FORCES ANALYSIS
FIGURE 16 VETERINARY PHARMACEUTICALS MARKET: VALUE CHAIN ANALYSIS
FIGURE 17 VETERINARY PHARMACEUTICALS MARKET: SUPPLY CHAIN ANALYSIS
FIGURE 18 VETERINARY PHARMACEUTICALS MARKET: ECOSYSTEM ANALYSIS
FIGURE 19 TRENDS AND DISRUPTIONS IMPACTING CUSTOMER BUSINESS
FIGURE 20 INVESTMENT/VENTURE CAPITAL SCENARIO IN VETERINARY PHARMACEUTICALS MARKET, 2021–2025
FIGURE 21 PATENTS APPLIED AND GRANTED, JANUARY 2015–DECEMBER 2025
FIGURE 22 TOP APPLICANT COUNTRIES/REGIONS FOR VETERINARY PHARMACEUTICALS PRODUCTS, JANUARY 2015–DECEMBER 2025
FIGURE 23 VETERINARY PHARMACEUTICALS MARKET: DECISION-MAKING FACTORS
FIGURE 24 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS FOR VETERINARY PHARMACEUTICAL PRODUCTS
FIGURE 25 KEY BUYING CRITERIA FOR TOP THREE END USERS
FIGURE 26 ADOPTION BARRIERS AND INTERNAL CHALLENGES
FIGURE 27 VETERINARY PHARMACEUTICALS MARKET: GEOGRAPHIC SNAPSHOT
FIGURE 28 NORTH AMERICA: EXPECTED GROWTH IN NUMBER OF VETERINARIANS, 2020–2030
FIGURE 29 NORTH AMERICA: PET POPULATION, 2024 (MILLION)
FIGURE 30 NORTH AMERICA: VETERINARY PHARMACEUTICALS MARKET SNAPSHOT
FIGURE 31 US: TOTAL PET HEALTH EXPENDITURE, 2020–2024
FIGURE 32 EUROPE: PET POPULATION, 2023 (MILLION)
FIGURE 33 ASIA PACIFIC: DOG POPULATION, BY COUNTRY, 2024
FIGURE 34 ASIA PACIFIC: CAT POPULATION, BY COUNTRY, 2024
FIGURE 35 ASIA PACIFIC: VETERINARY PHARMACEUTICALS MARKET SNAPSHOT
FIGURE 36 VETERINARY PHARMACEUTICALS MARKET: REVENUE ANALYSIS OF KEY PLAYERS, 2023?2025
FIGURE 37 VETERINARY PHARMACEUTICALS MARKET SHARE ANALYSIS, 2025
FIGURE 38 US: VETERINARY PHARMACEUTICALS MARKET SHARE ANALYSIS, 2025
FIGURE 39 EUROPE: VETERINARY PHARMACEUTICALS MARKET SHARE ANALYSIS, 2025
FIGURE 40 BRAND/PRODUCT COMPARATIVE ANALYSIS
FIGURE 41 VETERINARY PHARMACEUTICALS MARKET: COMPANY EVALUATION MATRIX (KEY PLAYERS), 2025
FIGURE 42 VETERINARY PHARMACEUTICALS MARKET: COMPANY FOOTPRINT
FIGURE 43 VETERINARY PHARMACEUTICALS MARKET: COMPANY EVALUATION MATRIX (STARTUPS/SMES), 2025
FIGURE 44 EV/EBITDA OF KEY VENDORS
FIGURE 45 5-YEAR STOCK BETA OF KEY VENDORS
FIGURE 46 ZOETIS INC.: COMPANY SNAPSHOT (2025)
FIGURE 47 MERCK & CO., INC.: COMPANY SNAPSHOT (2025)
FIGURE 48 BOEHRINGER INGELHEIM INTERNATIONAL GMBH: COMPANY SNAPSHOT (2025)
FIGURE 49 ELANCO ANIMAL HEALTH INCORPORATED: COMPANY SNAPSHOT (2025)
FIGURE 50 VIRBAC: COMPANY SNAPSHOT (2025)
FIGURE 51 CEVA: COMPANY SNAPSHOT (2025)
FIGURE 52 VETOQUINOL: COMPANY SNAPSHOT (2025)
FIGURE 53 HESTER BIOSCIENCES LIMITED: COMPANY SNAPSHOT (2025)
FIGURE 54 INDIAN IMMUNOLOGICALS LTD.: COMPANY SNAPSHOT (2025)
FIGURE 55 ANIMALCARE GROUP PLC: COMPANY SNAPSHOT
FIGURE 56 RESEARCH DESIGN
FIGURE 57 PRIMARY SOURCES
FIGURE 58 BREAKDOWN OF PRIMARY INTERVIEWS: SUPPLY-SIDE PARTICIPANTS
FIGURE 59 BREAKDOWN OF PRIMARY INTERVIEWS: DEMAND-SIDE PARTICIPANTS
FIGURE 60 BREAKDOWN OF PRIMARY INTERVIEWS: SUPPLY-SIDE AND DEMAND-SIDE PARTICIPANTS
FIGURE 61 MARKET SIZE ESTIMATION APPROACH: REVENUE SHARE ANALYSIS
FIGURE 62 MARKET SIZE ESTIMATION: REVENUE SHARE ANALYSIS (2025)
FIGURE 63 VETERINARY PHARMACEUTICALS MARKET: SUPPLY-SIDE ANALYSIS
FIGURE 64 TOP-DOWN APPROACH
FIGURE 65 VETERINARY PHARMACEUTICALS MARKET: CAGR PROJECTIONS FROM ANALYSIS OF DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES (2026–2031)
FIGURE 66 CAGR PROJECTIONS: SUPPLY-SIDE ANALYSIS OF VETERINARY PHARMACEUTICALS MARKET (2026-2031)
FIGURE 67 DATA TRIANGULATION
FIGURE 1 VETERINARY PHARMACEUTICALS MARKET SEGMENTATION
FIGURE 2 MARKET SCENARIO
FIGURE 3 VETERINARY PHARMACEUTICALS MARKET, 2024–2031
FIGURE 4 VETERINARY PHARMACEUTICALS MARKET: MAJOR STRATEGIES ADOPTED BY KEY PLAYERS, 2022–2025
FIGURE 5 DISRUPTIONS INFLUENCING GROWTH OF VETERINARY PHARMACEUTICALS MARKET
FIGURE 6 VETERINARY PHARMACEUTICALS MARKET: HIGH-GROWTH SEGMENTS, 2026–2031
FIGURE 7 ASIA PACIFIC TO REGISTER HIGHEST CAGR DURING FORECAST PERIOD
FIGURE 8 INCREASING PET CARE EXPENDITURE TO DRIVE MARKET
FIGURE 9 DRUGS SEGMENT AND CHINA DOMINATED MARKET IN 2025
FIGURE 10 ASIA PACIFIC TO REGISTER HIGHEST GROWTH RATE DURING FORECAST PERIOD
FIGURE 11 DEVELOPING ECONOMIES TO REGISTER HIGHER GROWTH RATES DURING FORECAST PERIOD
FIGURE 12 VETERINARY PHARMACEUTICALS MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES
FIGURE 13 PET POPULATION IN MAJOR MARKETS, 2022 (MILLION)
FIGURE 14 EUROPE: PET POPULATION, 2021–2023
FIGURE 15 VETERINARY PHARMACEUTICALS MARKET: PORTER’S FIVE FORCES ANALYSIS
FIGURE 16 VETERINARY PHARMACEUTICALS MARKET: VALUE CHAIN ANALYSIS
FIGURE 17 VETERINARY PHARMACEUTICALS MARKET: SUPPLY CHAIN ANALYSIS
FIGURE 18 VETERINARY PHARMACEUTICALS MARKET: ECOSYSTEM ANALYSIS
FIGURE 19 TRENDS AND DISRUPTIONS IMPACTING CUSTOMER BUSINESS
FIGURE 20 INVESTMENT/VENTURE CAPITAL SCENARIO IN VETERINARY PHARMACEUTICALS MARKET, 2021–2025
FIGURE 21 PATENTS APPLIED AND GRANTED, JANUARY 2015–DECEMBER 2025
FIGURE 22 TOP APPLICANT COUNTRIES/REGIONS FOR VETERINARY PHARMACEUTICALS PRODUCTS, JANUARY 2015–DECEMBER 2025
FIGURE 23 VETERINARY PHARMACEUTICALS MARKET: DECISION-MAKING FACTORS
FIGURE 24 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS FOR VETERINARY PHARMACEUTICAL PRODUCTS
FIGURE 25 KEY BUYING CRITERIA FOR TOP THREE END USERS
FIGURE 26 ADOPTION BARRIERS AND INTERNAL CHALLENGES
FIGURE 27 VETERINARY PHARMACEUTICALS MARKET: GEOGRAPHIC SNAPSHOT
FIGURE 28 NORTH AMERICA: EXPECTED GROWTH IN NUMBER OF VETERINARIANS, 2020–2030
FIGURE 29 NORTH AMERICA: PET POPULATION, 2024 (MILLION)
FIGURE 30 NORTH AMERICA: VETERINARY PHARMACEUTICALS MARKET SNAPSHOT
FIGURE 31 US: TOTAL PET HEALTH EXPENDITURE, 2020–2024
FIGURE 32 EUROPE: PET POPULATION, 2023 (MILLION)
FIGURE 33 ASIA PACIFIC: DOG POPULATION, BY COUNTRY, 2024
FIGURE 34 ASIA PACIFIC: CAT POPULATION, BY COUNTRY, 2024
FIGURE 35 ASIA PACIFIC: VETERINARY PHARMACEUTICALS MARKET SNAPSHOT
FIGURE 36 VETERINARY PHARMACEUTICALS MARKET: REVENUE ANALYSIS OF KEY PLAYERS, 2023?2025
FIGURE 37 VETERINARY PHARMACEUTICALS MARKET SHARE ANALYSIS, 2025
FIGURE 38 US: VETERINARY PHARMACEUTICALS MARKET SHARE ANALYSIS, 2025
FIGURE 39 EUROPE: VETERINARY PHARMACEUTICALS MARKET SHARE ANALYSIS, 2025
FIGURE 40 BRAND/PRODUCT COMPARATIVE ANALYSIS
FIGURE 41 VETERINARY PHARMACEUTICALS MARKET: COMPANY EVALUATION MATRIX (KEY PLAYERS), 2025
FIGURE 42 VETERINARY PHARMACEUTICALS MARKET: COMPANY FOOTPRINT
FIGURE 43 VETERINARY PHARMACEUTICALS MARKET: COMPANY EVALUATION MATRIX (STARTUPS/SMES), 2025
FIGURE 44 EV/EBITDA OF KEY VENDORS
FIGURE 45 5-YEAR STOCK BETA OF KEY VENDORS
FIGURE 46 ZOETIS INC.: COMPANY SNAPSHOT (2025)
FIGURE 47 MERCK & CO., INC.: COMPANY SNAPSHOT (2025)
FIGURE 48 BOEHRINGER INGELHEIM INTERNATIONAL GMBH: COMPANY SNAPSHOT (2025)
FIGURE 49 ELANCO ANIMAL HEALTH INCORPORATED: COMPANY SNAPSHOT (2025)
FIGURE 50 VIRBAC: COMPANY SNAPSHOT (2025)
FIGURE 51 CEVA: COMPANY SNAPSHOT (2025)
FIGURE 52 VETOQUINOL: COMPANY SNAPSHOT (2025)
FIGURE 53 HESTER BIOSCIENCES LIMITED: COMPANY SNAPSHOT (2025)
FIGURE 54 INDIAN IMMUNOLOGICALS LTD.: COMPANY SNAPSHOT (2025)
FIGURE 55 ANIMALCARE GROUP PLC: COMPANY SNAPSHOT
FIGURE 56 RESEARCH DESIGN
FIGURE 57 PRIMARY SOURCES
FIGURE 58 BREAKDOWN OF PRIMARY INTERVIEWS: SUPPLY-SIDE PARTICIPANTS
FIGURE 59 BREAKDOWN OF PRIMARY INTERVIEWS: DEMAND-SIDE PARTICIPANTS
FIGURE 60 BREAKDOWN OF PRIMARY INTERVIEWS: SUPPLY-SIDE AND DEMAND-SIDE PARTICIPANTS
FIGURE 61 MARKET SIZE ESTIMATION APPROACH: REVENUE SHARE ANALYSIS
FIGURE 62 MARKET SIZE ESTIMATION: REVENUE SHARE ANALYSIS (2025)
FIGURE 63 VETERINARY PHARMACEUTICALS MARKET: SUPPLY-SIDE ANALYSIS
FIGURE 64 TOP-DOWN APPROACH
FIGURE 65 VETERINARY PHARMACEUTICALS MARKET: CAGR PROJECTIONS FROM ANALYSIS OF DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES (2026–2031)
FIGURE 66 CAGR PROJECTIONS: SUPPLY-SIDE ANALYSIS OF VETERINARY PHARMACEUTICALS MARKET (2026-2031)
FIGURE 67 DATA TRIANGULATION
